Doctor of Philosophy by Piccolo, Stephen Richard







A dissertation submitted to the faculty of
The University of Utah
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy
Biomedical Informatics
The University of Utah
May 2011
Copyright c© Stephen Richard Piccolo 2011
All Rights Reserved








The dissertation of Stephen Richard Piccolo 
has been approved by the following supervisory committee members: 
 
Lewis J. Frey , Chair 11/18/2010 
 
Date Approved 
Philip S. Bernard , Member 11/18/2010 
 
Date Approved 
Lisa Cannon-Albright , Member 11/18/2010 
 
Date Approved 
Karen Eilbeck , Member 11/18/2010 
 
Date Approved 




and by Joyce A. Mitchell , Chair of  
the Department of Biomedical Informatics 
 




For decades, researchers have explored the effects of clinical and biomolecular
factors on disease outcomes and have identified several candidate prognostic markers.
Now, thanks to technological advances, researchers have at their disposal unprece-
dented quantities of biomolecular data that may add to existing knowledge about
prognosis. However, commensurate challenges accompany these advances. For exam-
ple, sophisticated informatics techniques are necessary to store, retrieve, and analyze
large data sets. Additionally, advanced algorithms may be necessary to account for
the joint effects of tens, hundreds, or thousands of variables. Moreover, it is essential
that analyses evaluating such algorithms be conducted in a systematic and consistent
way to ensure validity, repeatability, and comparability across studies. For this study,
a novel informatics framework was developed to address these needs. Within this
framework, the user can apply existing, general-purpose algorithms that are designed
to make multivariate predictions for large, hetergeneous data sets. The framework also
contains logic for aggregating evidence across multiple algorithms and data categories
via ensemble-learning approaches. In this study, this informatics framework was ap-
plied to developing multivariate prognisis models for human glioblastoma multiforme,
a highly aggressive form of brain cancer that results in a median survival of only
12-15 months. Data for this study came from The Cancer Genome Atlas, a publicly
available repository containing clinical, treatment, histological, and biomolecular
variables for hundreds of patients. A variety of variable-selection approaches and
multivariate algorithms were applied in a cross-validated design, and the quality
of the resulting models was measured using the error rate, area under the receiver
operating characteristic curve, and log-rank statistic. Although performance of the
algorithms varied substantially across the data categories, some models performed
well for all three metrics—particularly models based on age, treatments, and DNA
methylation. Also encouragingly, the performance of ensemble-learning methods
often approximated the best individual results. As multimodal data sets become
more prevalent, analytic approaches that account for multiple data categories and
algorithms will be increasingly relevant. This study suggests that such approaches
hold promise to guide researchers and clinicians in their quest to improve outcomes
for devastating diseases like GBM.
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Glioblastoma multiforme (GBM) is a highly aggressive form of brain cancer that
results in a median survival of 12-15 months, [2] a short duration relative to most
other cancers. [3] However, the length of time that GBM patients survive after
diagnosis is variable—some patients survive only a few weeks while others survive
many years [4]—a pattern that suggests that individual patient and tumor char-
acteristics influence tumor aggressiveness, responses to treatments, and ultimately
survival. Unfortunately, despite extensive research efforts to date, GBM survival has
not been extended appreciably at the population level. [5] An understanding of factors
associated with GBM survival time could help researchers and physicians identify
patients less likely to respond to standard treatments [1] and could help researchers
identify mechanisms driving disease severity.
The lack of progress in developing reliable methods to prospectively differentiate
between longer-term survivors (LTS) and shorter-term survivors (STS) likely results—
at least in part—from the complexity of interactions between clinical, demographic,
and treatment factors as well as from the biological complexity of tumor initiation and
progression. Various studies have identified an array of candidate prognostic factors
for GBM, [2,4,6–19] yet it has remained unclear how best to account for the effects of
multiple factors working in concert to affect prognosis. In response to this problem,
some researchers have proposed multivariate prognosis models. [1, 11, 19, 20] While
such studies have shown promise for aiding clinicians with the task of predicting a
patient’s prognosis, no existing model attempts to account for all candidate prognostic
factors for GBM—existing models typically account for a single category of molecular
data and one or more clinical variables such as age. Additionally, many algorithms
exist for developing multivariate prognosis models, but each GBM study has typically
2employed only one such technique. Two reasons for these limitations are apparent: 1)
it is economically infeasible for individual research labs to acquire multiple categories
of clinical and molecular data for a reasonably sized patient cohort, and 2) no
informatics framework has been available for performing analyses that compare and
combine the outputs of multiple algorithms in a systematic and consistent way.
Fortunately, a recent initiative by the United States National Institutes of Health has
resulted in a publicly available data repository—The Cancer Genome Atlas (TCGA)
[21]—that contains data for hundreds of GBM patients. This resource is unique in the
breadth of data it contains—TCGA contains thousands of data points representing
clinical characteristics, treatments administered, and molecular features profiling each
patient’s tumor. Such a resource enables an unprecedented opportunity to evaluate
previously reported prognosis models, to discover new candidate prognosis models,
and to make systematic comparisons across data categories and algorithms. Accord-
ingly, the overaching goal of this research was to develop an informatics framework to
perform such analyses and to apply the framework to an analysis of GBM survival.
1.2 Main Objectives
Having a vast array of data for each patient presents not only opportunities
but also challenges. One important challenge is to filter the data into variable sets
that represent the key factors influencing patient outcome and that ignore irrelevant
factors. A related challenge is to develop models that account for potentially intricate
combinations of heterogeneous factors that jointly affect patient outcome. In response
to such challenges, the statistics and machine-learning communities have developed
general-purpose algorithms designed to filter variable sets and to make multivariate
predictions in many diverse contexts; however, such algorithms have been applied only
minimally in the context of predicting GBM survival, so their potential usefulness
in this setting is unknown. Thus, one key objective of this research was to apply
machine-learning algorithms in this context.
Theory and practical application suggest that no single algorithm is universally
optimal for performing classification tasks. [22] One algorithm may be well suited
for extracting meaningful patterns from a particular class of patient data whereas a
3second algorithm may be less suitable for the task. However, the second algorithm
may, in turn, be more effective than the first algorithm on a different class of patient
data. The heterogeneous nature of the TCGA data provides further justification
to employ multiple algorithms—for example, some variables are naturally discrete
(e.g., sex, mutation status) while others are inherently continuous (e.g., age, gene
expression) and follow diverse numerical distributions. Thus, another key objective of
this research was to explore methods that combine the outputs of multiple algorithms
into a unified prediction for each patient.
Having identified a multivariate model that differentiates successfully between
two classes (e.g., LTS and STS), a subsequent challenge is to interpret the model.
This challenge can be especially difficult when the model contains a large number
of variables, a scenario often encountered with biomolecular-profiling data. Invi-
didual variables used in the model can be evaluated one at a time. However, it is
often desirable to interpret a model as a whole to better understand the underlying
mechanisms driving the model’s success. Gene-set enrichment analysis (GSEA) [23]
is one approach for interpreting sets of genomic variables. In GSEA, selected genes
are evaluated against known functional categories in an attempt to identify functional
categories that are associated with the genes more than would be expected by chance.
However, when only a subset of known genes have been profiled, a selection bias may
impact the results and subsequent intepretation. Consequently, another objective of
this research was to explore this bias and develop a method to account for it.
1.3 Hypotheses
In accordance with the main objectives, the following hypotheses were evaluated
in this study:
• Multivariate algorithms can be used to derive clinical and biomolecular models
that differentiate significantly between GBM patients who survived a relatively
long (LTS) or short (STS) time after diagnosis.
• Methods that aggregate evidence across multiple data categories and algorithms
can differentiate between LTS and STS better than using methods that use
4evidence from a single data category or algorithm.
• Biologically relevant aspects of the models can be identified via comparison with
prior knowledge and via accounting for gene-selection bias.
The remaining sections of this dissertation describe in further detail the research
that was performed in this study. The Background section describes the clinical
need motivating this study, prior research that has been conducted in this area, and
how this study aims to improve on prior work. The Methods section describes the
algorithms that were used to formulate GBM survival models, explains modifications
that have been made to existing approaches, and outlines the study’s experimental
design; additionally, this section describes the informatics framework that was devel-
oped and details at a technical level its advantages over other approaches. The Results
section outlines the findings of this study in substantial detail. The Discussion section
provides additional interpretation of the results, addresses notable side observations
that came about during the analysis, explains limitations of this study, and suggests
how the research could be developed further in future studies. Finally, the Conclusion




2.1 Univariate Predictors of GBM Survival
Over the past decades, researchers have searched for clinical, histological, and
treatment-associated factors that appear to shorten or lengthen overall GBM sur-
vival. An association between age at diagnosis and GBM survival has been reported
consistently and repeatedly. [4,6–15] Other factors reported to have some prognostic
relevance include Karnofsky Performance Status (KPS) (a measure of that patient’s
well being at the time of diagnosis), [8–14] extent of tumor resection, [9, 13–15]
radiation therapy, [6,14,16] and tumor necrosis. [7,9,24] In 2005, a phase III clinical
trial also suggested that treatment with Temozolomide, an oral alkylating agent,
extends survival in many patients. [2]
Due to technological advances, researchers have also searched for prognostic fac-
tors at the biomolecular level. Although many types of biomolecular alterations—for
example, DNA point mutations, DNA methylation changes, DNA amplifications and
deletions, and mRNA expression changes—have been observed regularly in GBM
tumors, [17, 25, 26] a prognostic relationship has been demonstrated for only a few
alterations, including IDH1 mutations, [17, 27] MGMT hypermethylation, [12, 18]
EGFR amplification, [13] CDK4 amplification, [14] MDM2 amplification, [13] and
FABP7 expression. [19] Unfortunately, for some of these associations, conflicting
results have been observed in other studies. [4, 12,14,16]
2.2 Multivariate Predictors of GBM Survival
Though it is promising that individual factors with prognostic relevance have
been observed for GBM, their value for predicting a given patient’s survival may be
limited, because individual factors often have a variable impact on survival. This
variability may, in part, result from combinations of factors that have cumulative or
6interacting effects. [28, 29] For example, in a recent study, simultaneous EGFR and
p53 alterations appeared to have a joint effect on GBM survival, whereas no effect
was observed for either alteration alone. [14] To account for such combinatory effects,
researchers have proposed multivariate models. [1, 11,19,20]
For example, in one study, multivariate techniques were applied to mRNA expres-
sion data for a group of GBM patients. [19] Liang, et al. examined whether GBM
patients—whose tumors by definition have similar histopathological features—could
be grouped into survival-associated subpopulations, based on genomewide mRNA
expression levels in the tumors. [19] They used agglomerative hierarchical clustering,
a popular unsupervised-learning algorithm, to divide patients into subpopulations
(clusters) that had relatively similar mRNA-expression profiles. Using a subset of
genes that were correlated with survival, they observed that the two upper-level
clusters had median survivals of 4 months and 25 months, respectively. Although
the generalizability of the model was not assessed, this finding suggested that mRNA
expression data may have potential to differentiate between LTS and STS.
Unsupervised-learning algorithms, such as the hierarchical-clustering method used
by Liang, et al., are designed to extract instrinsically meaningful patterns from data,
but they may not identify patterns that are optimally relevant to a particular outcome
(i.e., survival)—by nature, unsupervised-learning methods ignore outcomes. While
such approaches are useful in many scenarios (including when the outcome is un-
known), they may not be ideal when the researcher’s intent is to correlate independent
variables with a particular outcome. Thus, in complement to unsupervised-learning
methods, the statistics and computer-science communities have also developed a large
variety of supervised-learning algorithms designed to identify multivariate patterns
associated with outcomes of interest. Hundreds of supervised-learning algorithms
have been published in the literature and have been applied in many fields of study,
but such methods have been applied only minimally to GBM data in relation to
survival. [1, 11,30]
In one study, Lamborn, et al. used recursive partitioning analysis (RPA), [31]
a supervised-learning technique that divides patients into subpopulations according
to associations between combinations of independent variables and the outcome. [11]
7Lamborn, et al. investigated whether combinations of clinical variables could be
used to assign GBM patients to risk groups that had significantly different overall
survivals. Derived from a large sample of GBM patients who had been enrolled in
clinical trials and who had received radiation treatment, their RPA model was based
on age at diagnosis, KPS, and tumor anatomic site. When the model was evaluated
on the same data set from which it was derived, two-year survival estimates for
the groups were 65%, 35%, 17%, and 4%, respectively. In a follow-up analysis,
they also observed that this method could be used to detect survival-associated
subpopulations among patients that had received a particular treatment regimen.
Although the generalizability of the models was not assessed, the findings suggested
that multivariate models based on clinical data have potential to elucidate differences
in survival expectations among GBM patients as a whole or among patients receiving
a given treatment.
In a recent study, Colman, et al. applied supervised-learning methods to mRNA
expression data. [1] They explored the potential to predict an individual GBM pa-
tient’s survival status at the time of diagnosis. After examining multiple independent
data sets, they identified nine genes that consistently were differentially expressed
between patients who survived fewer than two years and patients who survived
longer. Then they developed a risk score based on the combined expression of the
nine genes: genes that were typically over-expressed were assigned a positive weight,
while under-expressed genes were assigned a negative weight. Then an optimal cutoff
value for distinguishing LTS from STS was identified using RPA. Colman, et al.
tested this method on a separate data set and found that the multigene score was an
independent, significant predictor of survival.
The results published by Colman, et al. suggest clinical viability for multivarate
prognosis models based on mRNA expression data. In fact, based on their findings,
the authors have marketed a test designed to distinguish LTS from STS in clinical
and research settings. [32] However, further exploration of the utility of such methods
is warranted. For example, Colman, et al. used univariate statistical approaches to
identify differentially expressed genes, yet multivariate approaches may reveal gene
subsets that influence survival jointly but not individually. [14] Additionally, the
8multigene scoring approach employed by Colman, et al. is basic and unsuitable for
data sets that contain discrete values. Accordingly, two foci of this study were to use
multivariate algorithms to filter variables sets and to make survival predictions using
multiple categories of clinical and molecular data.
2.3 Ensemble Predictors of GBM Survival
The studies described so far have been limited in at least two ways. Firstly,
each study evaluated a single category of GBM patient data (i.e., clinical, mRNA)
in isolation, whereas many types of prognostic factors (e.g., clinical, treatments,
biomolecular) have been observed for GBM patients and thus may influence GBM
tumor progression. [25] Secondly, each study reported applying only a single algorithm
to a respective data set, and it is likely that different algorithms perform better for
different categories of data or even for different subsets of patients. These limitations
appear commonly in other studies of GBM survival. Accordingly, other key foci
of this study were to evaluate the potential prognostic value of various categories
of patient/tumor data and the effectiveness of multiple algorithms for producing
accurate predictions of GBM survival.
Demonstrating the potential to develop prognostic models for a single category
of patient/tumor data provides an indication of the priority that should be placed
on collecting that data. However, intuition suggests that it should be possible to
improve prognostic models by aggregating insights across multiple data categories
and algorithms. In one study that implemented such an approach, Nigro, et al. [33]
acquired mRNA expression data and DNA copy-number data for a cohort of GBM
patients. Having applied filtering and clustering methods for the data categories
separately, they found that in both cases, one cluster contained predominantly STS
(< 2 years survival), while the other cluster had a combination of STS and LTS (>
24 months). Importantly, individual patients were not grouped identically for the
two data categories, an indication that the mRNA expression and DNA copy-number
data contained complementary prognostic information. Consequently, the authors
concluded that “analyzing genetic signatures on both DNA and RNA levels may
result in more robust molecular classification schemes than those derived from either
9experimental method alone” (p. 1685). [33] However, few such studies have been
conducted using multiple categories of patient/tumor data for the same set of patients.
Part of the reason may be that it has been economically infeasible for individual
research labs to obtain high-throughput molecular data—let alone multiple categories
of molecular data—for large patient cohorts. In fact, the patient cohort for the
Nigro, et al. study consisted of only 34 patients. Fortunately, the U.S. National
Cancer Institute and National Human Genome Research Institute have teamed to
invest in TCGA with the goal to “improve our ability to diagnose, treat, and prevent
cancer” by exploring “the entire spectrum of genomic changes involved in human
cancers”. [34] TCGA contains detailed clinical data (including time to survival) and
multiple categories of high-throughput biomolecular data for a cohort of over 300
GBM patients. Thus this vast resource provides an unprecedented opportunity to
explore multivariate prognosis models.
Although many supervised-learning algorithms exist, no single algorithm is uni-
versally optimal. [22] And generally speaking, the performance of a given algorithm
depends on the nature of the data to which it is applied. [22] Thus it may be useful
to apply multiple algorithms to potentially shed light on which algorithm(s) are well
suited (or not) to a particular category of data. However, lacking a priori knowledge
of which algorithm would perform best in a given scenario, ensemble methods—which
consider the outputs of multiple algorithms—have been suggested as a way to yield
better results than any single algorithm. [35] To gain advantage from combining the
outputs of multiple algorithms, it is desirable that the algorithms vary substantially
in the predictions that they make, a phenomenon known as classifier diversity. [36]
When classifier diversity exists (and in the common scenario where algorithms predict
imperfectly), the various algorithms commit prediction errors on different patients.
Ensemble methods attempt to capitalize on classifier diversity by aggregating the
collective insights provided by the individual algorithms—where one algorithm fails,
another algorithm may succeed. Many ensemble approaches have been proposed
in the literature, ranging in complexity from a simple majority vote [37] to more
advanced methods, such as those that assign weights to predictions based on the
perceived quality of the predictions. [38] In this study, a variety of such ensemble
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approaches have been applied to the problem of GBM survival prediction.
2.4 Assessing Clinical Relevance
Although it is an interesting academic exercise to apply multivariate algorithms to
patient data in novel ways, the value of such research can be increased substantially if
it can be shown that the methods have clinical utility. In the case of survival analyses,
clinical utility means demonstrating that patients who survive a relatively long period
of time can be distinguished from patients who survive a relatively short time. Having
separated patients into distinct groups, standard survival-analysis techniques (e.g.,
the log-rank test [39] and Kaplan-Meier curves [40]) can be used to assess the overall
differences in survival between the groups. A method that successfully separates
patients into survival-associated groups can be invaluble in clinical settings at the
time of diagnosis. [41] For example, if a patient knew her survival would likely be
relatively short, she might opt for more aggressive treatments and/or to enter a
(potentially risky) clinical trial. [42]
One advantage of unsupervised-learning techniques is that they assign patients to
discrete groups, so the overall survival of the groups can be compared in a straight-
forward way using survival-analysis techniques. Conversely, supervised-learning al-
gorithms rely upon an explicit outcome, which they attempt to predict. For the
analyses performed in this study, the outcome is survival, which is naturally a con-
tinuous variable, and obvious groupings among patient survival times may not arise
(as in GBM). Consequently, researchers often use an alternative approach—patients
surviving longer than a given number of days or years are placed in one group,
and patients surviving shorter than that threshold are placed in another group. By
dividing the patients into distinct groups, researchers are able to present findings that
are intuitive to clinicians and that can be assessed using survival-analysis techniques
that are familiar to clinicians. An additional reason for grouping patients this way
is that supervised-learning algorithms have traditionally focused more on problems
with discrete outcomes, and thus existing methods are more developed in this area.
Thus, in this study, the outcome variable is a discretized form of survival: patients
are designated as either LTS or STS based on whether the patient survived a specific
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number of days. (Details are outlined in the Methods section regarding the various
methods used to perform this discretization.)
2.5 Assessing Biological Relevance
If a model based on biomolecular data can be demonstrated to have high clinical
relevance to GBM survival, a logical next goal is to interpret the biological meaning
of the model. Identifying specific biological mechanisms that drive GBM tumor
aggressiveness could help bench researchers develop targeted treatments, potentially
leading to longer survival for patients subject to those biological mechanisms. In
addition to exploring biological mechanisms at a granular level, researchers have also
attempted to gain insights on the underlying functional categories associated with
the genes that appear to have most influence on the outcome. This class of methods,
commonly referred to as gene-set enrichment analysis (GSEA), [23] performs a func-
tional analysis on the top-level genes and identifies the known biological processes
or functions that are associated with the selected genes. Because some biological
processes have more genes associated with them than others, GSEA methods typically
correct for such bias. However, GSEA methods are typically designed for analysis of
high-throughput molecular data–such as mRNA-expression microarray data—that
profile almost every known gene. When custom (not genomewide) molecular assays
are used for molecular profiling, GSEA may need further refinement. In developing
such assays, researchers must decide a priori which molecular features to measure,
due to cost and/or technological restrictions. Because these decisions are at least
partially subjective, it is plausible that molecular features are selected in favor of
genes already believed to influence the disease(s) being studied. This potential
limitation is of particular relevance to researchers investigating multimodal data
sets like TCGA because each molecular-profiling platform measures a different set
of molecular variables. So having a method that could be applied more generally and




GBM data for this study were downloaded from the TCGA data portal [43] on
August 26, 2010. For each GBM patient, the portal contains clinical observations,
treatments that have been administered, histological observations of tumor samples,
number of days that patients survived, and biomolecular data that have been acquired
using various high-throughput profiling technologies. For this study, age, sex, and
Karnofsky performance status (KPS) were labeled as clinical variables. Treatment
variables were the following: radiotherapy, temozolomide, dexamethasone, lomus-
tine, bevacizumab, or other drug (indicating whether a given patient had received
any other type of drug treatment); each treatment variable contained binary values
indicating whether patients had received any of the given treatment. Histology
variables included in the analysis were number proliferating cells, percent tumor cells,
percent tumor nuclei, percent necrosis, percent stromal cells, percent inflammatory
infiltration, percent lymphocyte infiltration, percent monocyte infiltration, percent
granulocyte infiltration, percent neutrophil infiltration, percent osinophil infiltration,
presence of endothelial proliferation, presence of nuclear pleomorphism, presence of
palisading necrosis, and presence of cellularity. When a low value range (e.g., <5%
necrosis) was given, the range was rounded to bottom of the range; high-value ranges
(e.g., >95% tumor cells) were rounded up.
Molecular-level data representing DNA somatic mutations, DNA copy number
changes, DNA methylation states, mRNA expression levels, and miRNA expression
levels were also included in the analyses. These data were acquired using the fol-
lowing technologies: Sanger sequencing, Agilent Human Genome CGH Microarray
244A microarrays, Illumina DNA Methylation OMA002 and OMA003 custom pan-
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els, Affymetrix HG-133A microarrays, and Agilent 8 x 15K Human miRNA-specific
microarrays.
The TCGA data portal contains raw data as well as data that have been pre-
processed by the TCGA Consortium. [21] For somatic mutations, TCGA “Level 3”
data, which had been summarized at the gene level, were used. Somatic mutations
that had been marked as “silent” were excluded, based on an expectation that
synonymous mutations would by nature not have prognostic relevance. Additionally,
only mutations that had been validated and were considered “somatic” by the TCGA
Consortium were included. Finally, any gene that had fewer than two mutations was
excluded. For DNA copy number, the Level 3 data were mapped to the UCSC
hg19 version of the human genome, [44] and a mean value was calculated for each
chromosomal band. [45] For DNA methylation, Level 2 data were used (in the absence
of Level 3 data); these data contain “beta values” representing the proportion of
methylated molecules on the complementary probes for each locus. These data had
not been summarized at the gene level; thus, to get gene-level values, the mean beta
value across all probes associated with a given gene was calculated. For mRNA
and miRNA expression, Level 3 data, which had already been preprocessed and
summarized, were used.
For each patient, the overall survival time was calculated as the difference in days
between the date of initial pathologic diagnosis and the date of decease. Patients
having no recorded diagnosis date, having a pretreatment history, or missing >50
percent of data for a given data category were excluded. After performing this filtering
step, data for 313 GBM patients remained. Of those patients, 307 had data for at
least four data categories, and 100 had data for all categories. Table 3.1 lists the
number of patients and the number of data points for each category, along with the
proportion of missing values for each category. The All Data category represents a
combined data set containing the union of all other data categories.
3.2 Model Validation Procedure
Even when a multivariate algorithm is capable of fitting a model to a data set
with extremely high accuracy, the model may fail to generalize and thus have limited
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clinical relevance for the overall population. Cross validation is one technique for
assessing how well models generalize. Such an approach is essential, especially when
analyzing a data set like TCGA that is drawn from multiple institutions, includes
heterogeneously treated patients, and contains thousands of potential predictor vari-
ables.
In cross validation, the data instances (patients) are partitioned into sets of equal
size (or as close to equal as possible). In turn, each set is held separate for testing,
and the remaining instances are used to train a model. The trained models then are
used to predict the outcome of the respective test instances. One cross-validation
parameter that can be varied is the number of folds used. For example, in ten-fold
cross validation, the data set is divided into ten partitions, resulting in ten disjoint sets
of test instances. In leave-one-out cross validation, each test set contains only a single
instance, and the remaining instances are used for training. In this study, ten-fold
cross validation was used. Where possible, stratification was also used; stratification
attempts to spread instances from each class (e.g., LTS, STS) evenly across the folds.
In order to estimate optimal parameters for training a model, this study also
employed nested cross validation; with this approach, instances in each training set are
further subdivided into internal training and test sets; the parameters that perform
best internally are then used to train models on the outer training sets. Nested cross
validation provides performance estimates that approximate what can be obtained
on independent test sets. [46]
Having assigned patients to cross-validation folds, variable-selection approaches
were applied to the training sets. The purpose of such approaches is to reduce the
effect of noise in the data by focusing the models on variables that are most relevant to
the outcome. Having ranked the variables for each data category, the top-1, 5, 10, 50,
100, 500, or 1000 variables (if that many were available) were identified for each outer
training set. Because the optimal number of variables to include in a given model was
unknown, a similar selection procedure was applied to the internal cross-validation
folds. The number of top-ranked variables, n, that performed best on each training
set—based on lowest average area under the receiver operating characteristic curve
(AUC) across the internal folds—was considered optimal. Classification algorithms
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then used the best n features to train a model and predict the survival status of
patients in the respective outer folds. This procedure was performed independently
for each combination of data category, feature-selection approach, and classification
algorithm.
3.3 Variable Selection Approaches
In filtering variable sets, four selection approaches were used.
The first approach, None, is simply to perform no filtering. Two reasons for using
this approach may have merit: 1) it is possible that every variable contributes some
information, so excluding any variable may reduce classification performance, and
2) many classification algorithms have intrinsic techniques for filtering variables that
are particularly well suited to those algorithms, so pre-filtering with a contradictory
approach may negatively impact classification performance.
The second selection approach, prior knowledge filtering, requires a manual litera-
ture review to identify variables that have been reported to bear prognostic relevance
for each of the data categories. The purpose of applying this technique is to identify
all GBM prognosis variables for which the scientific community has reached some
consensus. Selecting variables based on prior knowledge also sets a baseline against
which the quantitative algorithms can be compared. For this study, a variable
was considered to constitute prior knowledge if two or more articles, published in
peer-reviewed journals, had reported the variable to be prognostic for GBM. Two
exceptions to this rule were allowed: 1) if only one article had reported any candidate
prognosis variable for a given data category, the variables from that article were used,
or 2) if a single study had validated candidate variables across multiple independent
data sets, those variables were considered robust and given preference over variables
reported in separate studies. Few articles researching the prognostic relevance of
miRNA expression have been published to date, so a single article was considered
sufficient for that category. The Colman et al. mRNA expression signature was
derived from multiple independent studies and thus was used. Table 3.2 lists each
data category along with the prior-knowledge variables that were selected for each
category.
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Another selection approach used in this study was the Support Vector Machines-
Recursive Feature Elimination (SVM-RFE) algorithm. [47] SVM-RFE is based on
Support Vector Machines, a powerful classification algorithm that assigns a weight
to each variable, quantifying its ability to discriminate the classes. SVM-RFE uses a
backward search: variables with the lowest weights are removed in an iterative fashion,
and variables are ranked according to the order in which they are eliminated. [47]
SVM-RFE has been shown to perform well on high-dimensional data sets with com-
plex dependencies among variables. [47] The implementation of this algorithm in the
Weka software package [48] was used in this study. The algorithm was configured to
eliminate 10% of variables in each iteration; when 10 or fewer variables remained, one
variable was eliminated in each iteration. Otherwise, default configuration settings
were used.
The final variable-selection approach was the RELIEF-F algorithm. [49] For a
random subset of instances (i.e., patients in this case), RELIEF-F compares each
instance against other instances of the same class (i.e., LTS or STS) and of a different
class; it then calculates a score for each variable based on whether values are similar
for instances of the same class and dissimilar for instances of a different class. [49] The
resulting score is a continuous value with higher numbers signifying a better ability to
differentiate and zero/negative values signifying no ability to differentiate. This study
used the Weka implementation of this algorithm with default configuration settings.
3.4 Classification Algorithms
In TCGA, some data categories contain hundreds or thousands of independent
variables. Additionally, variables vary not only in their semantics but also in their
scales of measurement. [50] Consequently, classification algorithms used in this study
needed to be capable of handling a large number of variables and multiple variable
types. The following algorithms meet these criteria and were employed in this study:
C5.0 Decision Trees, Na¨ıve Bayes Classifier (NBC), and Support Vector Machines
(SVM). Each of these algorithms has been applied broadly in a variety of contexts
and represents a considerably different algorithmic approach.
The C5.0 Decision Trees algorithm [51] is conceptually similar to the RPA al-
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gorithm (used in the Lamborn, et al. study [11]) in that it uses combinations of
variables to assign patients to subgroups that are homogeneous in relation to the
outcome variable; however, unlike RPA, C5.0 Decision Trees is designed to handle
both continuous and discrete variables, [52] handle missing values, perform well on
large data sets, and account for intervariable dependencies.
NBC is based on Bayes’ Theorem of conditional probabilities and calculates the
class’ posterior probabilities as the product of the conditional probabilities for each
variable. [53] For simplicity, NBC assumes independence between variables; yet de-
spite its simplicity, NBC often performs as well as or better than more sophisticated
algorithms. [54] For this study, the Weka implementation of this algorithm was used.
Instead of the default settings, which assume that continuous variables follow a normal
distribition (which is not always the case in the TCGA data), a nonparametric kernel
density estimator was used to characterize continuous variables. This method has
been shown to reduce errors compared to the normality assumption. [55]
The SVM algorithm [56] uses a mathematically derived hyperplane to separate
instances of different classes; the instances lying on the hyperplane’s margin constitute
support vectors, and the algorithm seeks a maximal margin between the hyperplane
and the support vectors. [57] For this study, the Weka wrapper of the LibSVM library
[58] and the radial-basis function kernel (default setting) were used.
3.5 Ensemble Learning Approaches
Ensemble-learning methods are designed to create aggregate predictions based on
evidence from multiple individual predictions. For this study, a variety of existing
ensemble approaches were applied, and modified versions of existing approaches were
developed. In performing ensemble learning, predictions from each combination of
data category, feature-selection approach, and classification algorithm were consid-
ered. (Predictions for the All Data category were excluded.)
The first and simplest ensemble approach, majority vote, [37] counts the number
of predictions a patient received for a given outcome (i.e., LTS or STS) and makes
an aggregate prediction in favor of the outcome that received the most votes; in
situations where each outcome received the same number of votes, the predicted
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outcome is selected at random.
An advantage of majority vote is its simplicity; however, because each prediction is
given an equal weight, the aggregate prediction may be influenced heavily by incorrect
individual predictions. The second approach, simple weighted vote, [38] attempts to
place most emphasis on the individual predictions it believes to be most informative.
The implementation used in this study assigns a weight to each individual prediction
based on the AUC attained via nested cross validation for the relevant combination
of data category, feature-selection algorithm, and classification algorithm. Squared
weighted vote squares the weights used in the simple weighted vote in an attempt
to place exponentially higher emphasis on predictions that perform best in nested
cross validation. Two additional novel approachs—LTS predictive-value weighted vote
and STS predictive-value weighted vote—assign weights based on the percentage of
times (learned via nested cross validation) that patients were predicted correctly
as being LTS or STS, respectively. These approaches were motivated by the need to
improve predictive performance in data sets that have an unbalanced class distribution
and thus may favor predictions for either class. For example, STS predictive-value
weighted-vote places the most emphasis on predictions that it believes are effective for
identifying STS correctly and thus may perform relatively well on data sets containing
a small proportion of STS.
For each patient, the Select Best approach makes an aggregate prediction based
on the individual prediction that received the highest weight (AUC).
Two additional ensemble methods use the posterior probabilities assigned by
individual classification algorithms. The mean probability method averages the prob-
abilities for each outcome across all predictions—the outcome with the highest mean
probability is selected. Weighted mean probability assigns a weight, based on the
inner-fold AUC, to each probability, and then calculates the mean for each outcome.
Finally, Stacked Generalization uses the posterior probabilities from the original
predictions and trains a second-level classification algorithm to make aggregate predic-
tions based on those values. [59] In stacked generalization, any classification algorithm
can be used for the second-level predictions; however, this study used C5.0 Decision
Trees because it is designed to handle dependencies between attributes (in this case,
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predictions)—a condition that would be expected to occur when first-level algorithms
make similar predictions—and because its models are easily interpretable.
3.6 Outcome Discretization
In accordance with previous studies of GBM survival, [1, 30, 33] each patient was
designated as either a longer-term survivor (LTS) or shorter-term survivor (STS).
In the literature, several survival thresholds have been used to distinguish LTS from
STS; one of the most common thresholds is two-year survival [1,33]; however, in other
studies, different thresholds have been used. [12, 60] In this study, various survival
thresholds were used in an exploration of the effects the threshold has on performance.
Two-year survival was used in the initial experiments: patients surviving longer than
two years were labeled as LTS, while patients surviving shorter were labeled STS. In
a subsequent experiment, an empirical method was used to estimate which split point
would result in the best classification performance. [61] This method evaluates many
split points via an optimization procedure, attempting to split the patient population
into two groups that are subject to “different underlying disease mechanisms” (p.
95). [61] In this approach, 1) a series of candidate split points are determined: patients
are sorted by their respective survival times, and the median survival separating each
set of adjacent patients constitutes a candidate split point; 2) for each split point,
patients are designated as either STS or LTS, depending on their actual survival time;
3) cross validation is used to calculate an error rate at each split point; and 4) the
split point that results in the lowest error rate (compared to the error rate that would
have been achieved if the majority class had been predicted by default) is selected.
In implementing the split-point selection procedure, several modifications differed
from the published approach. The original authors used the C4.5 Decision Trees
algorithm for the cross-validation step; however, Quinlan has released an updated
version of the algorithm called C5.0 Decision Trees, which was used in this analysis.
Additionally, the published method selects the split point that performs best on the
full data set; however, this approach may result in models more likely to overfit the
data and thus that fail to generalize to external data sets. Consequently, in this
study, a split point was selected separately, via nested cross validation, for each outer
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cross-validation fold. Finally, because of the large number of variables in the TCGA
data set and because of the higher computational burden of performing nested cross
validation, 10-fold cross validation was used rather than leave-one-out cross validation
(as used by the original authors).
3.7 Performance Metrics
Having performed cross validation, a survival prediction existed for each patient.
The quality of the predictions was measured using various metrics: error rate, AUC,
and the log-rank survival statistic.
The error rate is calculated as the percentage of test instances misclassified across
all folds. (Of related interest is the proportion of patients of either class that were
predicted accurately.)
The AUC considers the posterior probabilites produced by the classification algo-
rithms; these probabilities represent the confidence with which the predictions were
made. In calculating the AUC, various confidence thresholds are used, and the true
positive rate is measured against the false positive rate across all thresholds.
In many machine-learning studies, the error rate and AUC are the performance
metrics of primary interest; however, in this study, the outcome variable (survival) is
naturally continuous. Thus, the performance was also measured using the log-rank
statistic. [39] The overall survival times of patients predicted as LTS were compared
against the overall survival times of patients predicted as STS. Subsequently, Kaplan-
Meier curves [40] were used to create a visual representation of the overall survival
differences between the two groups. The R project [62] and its survival package [63]
were used for calculating the log-rank statistic and producing the graphs.
The performance of the ensemble approaches was measured using the same metrics
by which individual algorithms were measured.
3.8 Custom Software Requirements
The complex nature of the analyses that were performed in this study necessitated
a custom software implementation to orchestrate the various analysis steps. The
name of this software package is ML-Flex because it is designed to perform machine-
learning analyses in a flexible and extensible way. ML-Flex is a command-line tool,
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written in the Java programming language. Although ML-Flex was developed for
the analyses performed in this study, its extensible nature also suits it well for more
general application. The following paragraphs explain the requirements that were
met by ML-Flex, along with brief explanations of the software’s architecture.
A vast array of multivariate algorithms have been published; however, the algo-
rithms are implemented in a variety of programming languages, have inconsistent
interfaces, and use a variety of file formats. Additionally, due to the heterogeneous
nature of the methods used to acquire and/or preprocess each category of TCGA
data, a variety of text-based data formats have been used to represent the data. Thus,
ML-Flex’s first requirement was to parse arbitrary data formats and store them in
local files that use a common data structure. Having collected and consolidated input
data, a second requirement was to transform data values based on criteria specific to
that type of data—for example, the DNA methylation data in TCGA are recorded
at the probe level, but a gene-centric value needed to be computed across all probes
for a given gene.
Having processed and stored the transformed data, the next requirement was
to apply variable-selection and classification algorithms to the data. Because the
TCGA data sets are large, and nested cross validation—a computationally intensive
procedure—needed to be performed multiple times, the software also needed to exe-
cute in parallel across multiple computing nodes and multiple processing cores within
each node, thus decreasing the amount of time required to complete the analyses.
Prior to performing the analyses, third-party software libraries with implementa-
tions of the algorithms were identified; however, no single library implemented all the
algorithms. Furthermore, Weka is written in the Java programming language, while
C5.0 Decision Trees is written in C. Consequently, an additional requirement was that
ML-Flex interface extensibly with third-party software written in many programming
languages. Accordingly, ML-Flex needed to contain logic for formatting the data in
whatever structure was required by a given third-party tool. For third-party software
packages that are not accessible via a Java application programming interface, ML-
Flex interfaces with them in the following way: 1) a formatted text file is saved to
the local file system, 2) the third-party software is invoked via command-line calls
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using the Runtime class in Java, and 3) after the software returns an exit code, the
software’s output files are parsed, and the results are recorded. Thus each software
package can operate natively, without requiring any language-specific wrappers.
Another important requirement was that ML-Flex output the analysis results to
structured text files that could then be imported into statistical packages and graphics
libraries to assist in reporting the results.
3.9 Custom Software Features
Using Java’s object-oriented nature, several abstract classes were developed within
ML-Flex. The abstract classes contain generic functionality for the main program-
ming logic and specify default parameters. For example, to extract and transform the
raw data, an abstract class called AbstractDataProcessor orchestrates the process of
parsing input files, transforming data values, and storing transformed data. Concrete
classes contain the specific logic and parameters required to extract and transform
each category of raw data. This extensible design makes it possible to add new
categories of data to analyses with minimal coding effort.
No existing software package contained implementations of all ensemble-learning
approaches that were performed in this study, so this functionality was added to
ML-Flex. ML-Flex uses an abstract class to retrieve the outputs of individual algo-
rithms and assign weights to individual predictions. It then uses concrete classes to
implement the specific logic for the various ensemble approaches.
Although implementations of nested cross validation exist in third-party software
packages, a custom implementation of this logic was incorporated into ML-Flex
because it was central to the TCGA analyses and because the custom implementation
facilitated executing tasks in parallel.
To process the data in parallel, a simple, coarse-grained architecture was imple-
mented. This approach is designed to operate in a cluster-computing environment
with minimal duplication of computations, without deadlocks, and with no need to
communicate directly across processing nodes or threads. For example, for vari-
able selection, ML-Flex instantiates a list of Java objects indicating each unique
combination of data category, algorithm, and cross-validation fold; then using the
java.util.concurrent framework, multiple, independent threads access the file
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system to check whether a given combination has been processed and the results
have been stored; if the combination has not been processed, the thread checks
the file system for an empty, correspondingly named lock file indicating that the
combination is currently being processed by another thread; if no lock file exists,
the thread attempts to use an atomic transaction to create the lock file; having
successfully created the lock file, the thread performs variable selection, the results
are stored on the file system, and the lock file is deleted. Similar logic is used to
perform classification tasks.
Even though ML-Flex is designed to process data quickly via parallelism, the
design of ML-Flex sacrifices some performance in favor of scalability and flexibility.
Although computing nodes operate independently and thus do not communicate
directly to optimize performance, any number of computing nodes may be used, and
individual computing nodes may run any operating system that supports the various
software components. (However, it is essential the clustering environment employ a
shared file system that allows atomic file creation.) Because text files track processing
status, ML-Flex is restartable, a desirable feature in cluster-computing environments
where server reliability may be limited. Before a job is restarted, lock files simply
must be deleted to clear the processing queue. Additionally, ML-Flex’s design makes
it possible to assign additional computing nodes to a job even after the job is already
running.
3.10 Custom Software Validation
Any custom software implementation requires a concerted effort to verify that the
software functions properly. ML-Flex was evaluated on various data sets for which
the expected outcome (or at least an approximation thereof) was known in advance.
For the first validation, the actual survival values of the TCGA patients were used.
As a preliminary step, patients who survived longer than the median were designated
as LTS, and the remaining patients as STS. Then for each patient, 900 continuous
values were generated at random using the standard normal distribution and assigned
to the patient. Subsequently, 100 binary values were generated for each patient, and
the symbols were shuﬄed at random. The resulting data set contained 1000 variables,
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each of which should be expected to have no ability to discriminate between LTS and
STS. The purpose of creating and evaluating this data set was to ensure that the
software contained no obvious problem that would give a positive result when none
was expected.
The second validation data set was generated using an approach similar to what
was used for the first set. However, in this case, three of the continuous random values
were increased by 50 points for each STS. Additionally, two of the binary values were
generated such that STS were always assigned a value of zero, while LTS were always
assigned a value of one. Although this data set mostly contained randomly generated
noise, it should be expected that 1) the variable-selection algorithms would place the
highly discriminatory variables at the top of their ranked lists, and 2) the classification
algorithms would be able to discriminate perfectly (or at least nearly so) between LTS
and STS. The purpose of evaluating this data set was to ensure that when an obvious
signal did exist, it could be found.
The final validation data sets were downloaded from the UCI Machine Learning
Repository, [64] which contains various “real-world” data sets that have been eval-
uated in many machine-learning studies over the years. Although few of the data
sets are cancer related, the purpose of this validation step was to ensure that the
classification results obtained on these data sets were similar to results that have
been achieved in other studies; achieving similar results would also suggest that
the software developed for this study could perform effectively on data sets with
varying levels of expected discrimination. The UCI data sets used for validation
were Iris, Breast Cancer (Wisconsin), [65] Hepatitis, Horse Colic, Ionosphere, Pima
Indians Diabetes, Statlog (Australian Credit Approval), Statlog (Heart), Tic Tac Toe
Endgame, Connectionist Bench (Sonar), and Congressional Voting Records. With
the exception of Iris, each of these data sets contain two classes; for consistency, Iris
was separated into two separate data sets—one containing setosa and versicolor data
(which are linearly separable), and the other containing versicolor and virginica data
(not linearly separable).
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3.11 Bias Correction Procedure for Gene
Set Enrichment Analysis
The GOstats [66] package was used to perform GSEA. GOstats uses the hypergeo-
metric distribution to correct for functional categories that have a relatively large (or
small) number of genes associated with them and thus would be more (or less) likely
to reveal associations with the selected genes. Using this package, an association was
tested between genes in top-performing models and biological pathways in the Kyoto
Encyclopedia of Genes and Genomes (KEGG) homo sapiens database. [67]
To correct for potential gene-selection bias, the following method was used. For a
given data category, a subset of genes of the same size as the top-performing model
was randomly selected from the full set of genes profiled. GSEA was performed for
the random gene set, and the resulting p-values were recorded for each pathway.
When no result was returned for a pathway, the p-value was 1.0 by default. The
same process was repeated 1000 times. For each pathway, an empirical p-value was
then calculated by comparing the actual p-value with the distribution of p-values for
randomly selected gene sets. Empirical p-values below 0.05 were considered to be
statistically significant.
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Table 3.1. Summary of TCGA patients and variables included in the analyses for
each data category after filtering steps were performed.
Data Category # Patients # Variables Proportion Missing Data
Clinical 313 3 0.081
Treatments 313 6 0.004
Histology 313 6 0.006
DNA Methylation 188 2189 0.020
Somatic Mutations 112 154 0.000
DNA Copy Number 305 320 0.000
mRNA Expression 279 12042 0.000
miRNA Expression 276 534 0.000
All Data 313 15254 0.156
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Table 3.2. Variables that have been associated with GBM prognosis in the literature






Somatic Mutations IDH1, TP53
DNA Copy Number 7p, 9p, 10q23, 12q, 19p
mRNA Expression PDPN, AQP1, CHI3L1, RTN1, EMP3
GPNMB, IGFBP2, OLIG2, LGALS3
miRNA Expression hsa-miR-196a, hsa-miR-196b
CHAPTER 4
RESULTS
4.1 Validation Experiment: Simulated Data
With and Without Structure
Table 4.1 lists results of the validation experiment that was performed using
random, simulated data for which no significant separation between LTS and STS
was expected. Indeed, the algorithms differentiated poorly between LTS and STS. In
fact, in most cases, the error rate and AUC values were slightly worse than would be
expected by chance (0.498 and 0.500, respectively). None of the log-rank p-values were
below 0.05. Figure 4.1 displays an ROC curve for the result obtained with the C5.0
Decision Trees classification algorithm (with no variable selection). As expected, the
curve lies close to the x = y line, which represents the result that would be expected
by random chance. Figure 4.2 displays the associated Kaplan-Meier curves, which
overlap substantially (as expected). Table 4.2 lists results for the ensemble-learning
approaches. Again as expected, the results are similar to what would be expected by
chance.
Table 4.3 lists results of the validation experiment in which a subset of variables
were simulated to separate LTS from STS, whereas the remaining variables were
random noise. As expected, the algorithms separated the two classes perfectly,
resulting in error rates of 0.0, AUC values of 1.0, and extremely low log-rank p-
values; these results approach the upper limits of performance that could be expected
from the TCGA GBM data. Figure 4.3 and Figure 4.4 display an ROC curve and
Kaplan-Meier curves, respectively, for the results obtained using the C5.0 Decision
Trees classification algorithm (and no variable selection). Table 4.4 lists results for
the ensemble-learning approaches; these, too, performed extremely well, as expected.
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4.2 Validation Experiments: UCI Machine
Learning Repository Data
Table 4.5 list results of validation experiments that used data from the UCI Ma-
chine Learning Repository. No single algorithm always performed better than the rest.
And in many cases, predictive performance varied substantially from one algorithm to
another on a given data set. The SVM algorithm performed considerably worse than
C5.0 Decision Trees and NBC on the Statlog data sets but considerably better on the
Tic Tac Toe data. Such variability illustrates the concept of classifier diversity—some
algorithms are better suited than others to particular data sets. Accordingly, the
ensemble-learning approaches often performed better than individual algorithms (see
Table 4.6), though the results were mixed overall. Notably, the performance of the
ensemble-based approaches was highly consistent across the various approaches.
As a means of comparison, these tables also list results that were reported for
the UCI data sets on TunedIT.org, a web site that allows researchers to report
classification results for a wide variety of algorithms. In these tables, the TunedIT
values represent the mean error rate across all Weka classifiers that fall under the
bayes, functions, and trees classifier categories. For every data set except Ionosphere,
the TunedIT results fall within the range of results that were obtained using ML-Flex.
It is reasonable that the TunedIT results would vary moderately from the ML-Flex
results because the TunedIT results were obtained using a variety of algorithms and
configuration settings.
4.3 TCGA Experiment 1: Full Data
Set, Two-Year Survival
In an initial exploration of prognostic models that could be derived with the
algorithmic variable-selection approaches, an initial experiment was performed using
the full TCGA data set and two-year survival as the survival split point. Results
obtained using SVM-RFE variable selection are listed in Table 4.7. (Results for the
remaining variable-selection approaches are listed in Tables 4.8 and 4.9.)
A relatively high AUC value (0.683) and a significant log-rank p-value (0.0159)
were observed for the NBC models based on age, KPS, and gender data. However,
when variable selection was performed—thus limiting the models to a single clinical
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variable—the models became less stable and performed relatively poorly. This result
suggests that age, KPS, and gender each contributed some information that helped
differentiate between patients who survive longer or shorter than two years.
The second-lowest p-value (0.00104) and highest AUC value (0.705) were attained
by NBC models trained on treatment variables. This result suggests that patients
surviving longer than two years received different overall treatments from patients
surviving less than two years. A look at the underlying data reveals a clear trend
between patient survival and the overall number of treatments received (see Figure
4.5). Two possible explanations for this trend are that 1) the more treatments
a patient receives, the better her survival expectation, or 2) the longer a patient
survives, the more treatments she is likely to receive. The latter would likely be a
confounding effect.
When SVM-RFE variable selection and the SVM classification algorithm were
applied, DNA methylation models attained significance according to the log-rank
statistic (see Figure 4.6; p = 0.427). Interestingly, the models performed best when
the top-1000 ranked genes were included, and predictive performance tended to
improve as the number of genes increased (see Figure 4.7). Many studies have demon-
strated an association between gene-specific methylation and outcome—including a
relationship between MGMT methylation and GBM survival [2]—but global methyla-
tion patterns have also been suggested to influence tumor initiation and progression.
For example, recent research suggests that global hypomethylation contributes to
oncogene activation, loss of imprinting, and decrease in genomic instability. [68] On
the other side of the spectrum, global hypermethylation can silence transcription of
many genes—including tumor suppressors—and is recognized as a common molecular
abnormality across various cancers. [69] In fact, some cancer studies have shown a
prognostic relationship between methylation patterns across many genes even when
no relationship existed for the individual genes. [69] In the TCGA methylation data,
58.4% of profiled genes were more highly methylated in STS than in LTS (based on
mean difference, see Figure 4.8), a trend that suggests a slight bias toward hyperme-
thylation in the most aggressive tumors.
The best-performing somatic-mutation models contained 50 genes, but it appears
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the presence of such a large number of genes resulted in models being overfit to
the training data, which resulted in poor generalization. The top-ranked genes (e.g.,
PRAME, FRAP1, GRM1, PTCH1, EPHA3) were mutated differentially between LTS
and STS; however, because many of the genes were mutated infrequently (often only
two to three times across the population), the models failed to generalize. It may be
that limiting the analysis to genes that are mutated more frequently would stabilize
variable selection and result in better-performing models.
When all data were combined into an aggregate data set, C5.0 Decision Trees
models performed well according to the log-rank statistic (p = 0.00474) and AUC
0.452). Perhaps most notable about this result is that none of the C5.0 models
attained significance for individual data categories; however, when all data were
combined, the algorithm was much more successful at separating LTS from STS. The
interpretable nature of C5.0 Decision Trees makes it feasible to investigate hypotheses
about factors that may interact across data categories to affect survival. For example,
when the C5.0 rule learner was applied to the full data set, it suggested that patients
would be STS if they received lomustine treatment and had relatively low methylation
for either CD86 or IRAK3; conversely, it suggested that patients would be LTS if they
received lomustine treatment but had relatively high methylation for both CD86 and
IRAK3. These rules held true for approximately 26/32 (82%) of patients who received
lomustine. Such rules could guide researchers in developing treatments tailored to a
patient’s tumor–molecular profile; however, the true clinical and biological relevance
of such rules can only be speculated until further validation.
Although the NBC algorithm appears to have performed best overall, classifier
performance varied substantially across algorithms in this experiment. This higher
classifier diversity may be one reason the ensemble approaches resulted in AUC
values that were consistently higher than most individual classifiers (see Table 4.10).
However, the best performing ensemble approach was Select Best (AUC = 0.676,
p = 0.00762). By nature, Select Best is influenced strongly by the best individual
performers, which in this case were models based on clinical and treatments data.
In many cases, the ensemble approaches predicted all patients as LTS, likely an
indication that the ensemble approaches were influenced heavily by class imbalance
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between LTS and STS. However, as expected, the LTS predictive-value weighted vote
method helped counter some of the effects of class imbalance in comparison to the
majority vote and simple weighted vote methods.
One result from this experiment was counterintuitive and helps illustrate that
care must be taken to interpret the results. In this experiment, the lowest log-rank
p-value was attained when the SVM-RFE and NBC algorithms were applied to the
clinical data. Interestingly, Kaplan-Meier curves for the predictions reveal that the
subset of patients predicted as LTS survived a significantly shorter time compared
to the remaining patients (see Figure 4.9; p = 4.46e-05), an unexpected trend. One
limitation of the log-rank statistic is that significance can be attained even when
predictions are inaccurate; consequently, when evaluating survival-status predictions
it is essential also to examine Kaplan-Meier curves visually. A second important
observation is that the error rate and AUC sometimes conflict with each other. In
this case, the error rate was 0.220, substantially worse than the baseline expected by
chance (0.169). Conversely, the AUC was 0.590, substantially better than expected by
chance (0.500). The reason for this discrepancy is that NBC was unable to decipher
whether 23 of the patients were LTS or STS and thus predicted the two classes with
equal probabilities. Then by default, NBC designated these patients as LTS—an
apparently arbitrary decision. Of the 23 patients, 22 were actually STS. This explains
not only why the error rate was low but also why the LTS-predicted patients had
low survival as a group. However, because the AUC is not sensitive to arbitrary
thresholds, it indicated reasonably overall good performance, as illustrated by the
ROC curve for this result (see Figure 4.10).
4.4 TCGA Experiment 2: Prior Knowledge
Variables, Two-Year Survival
The second experiment on TCGA data was performed using the prior-knowledge
variables and two-year survival as a split point. Table 4.11 lists results for the
individual classification algorithms.
Two results attained statistical significance via the log-rank test: NBC models
trained on TP53 and IDH1 somatic mutations (p=0.00479, see Figure 4.11) and
NBC models trained on mRNA expression levels (p=0.00599, see Figure 4.12). No
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other result was statistically significant.
Interestingly, even though the NBC somatic-mutation models attained significance
via the log-rank test, the AUC value (0.520) was only slightly higher than what
would be expected by random chance (0.500). Additionally, the error rate (0.196)
was slightly worse than would be expected by chance (0.196). Taken together, these
results demonstrate again a key observation that arose in this study: no single metric
is suitable in isolation to quantify classification performance. In this case, the log-rank
statistic highlights a small subset of patients who were predicted as LTS. Of those
patients, only three survived longer than two years. However, as a group, the patients
predicted as LTS had significantly longer survival than patients predicted as STS. In
fact, two of the LTS-predicted patients survived 603 and 691 days—values that were
close to the survival threshold. Thus while these patients were misclassified—thus
impacting the error rate and AUC—the NBC algorithm still identified a patient subset
with potential clinical relevance. Indeed, recent research has suggested that IDH1
mutations offer a survival advantage, [17,27] which may partially explain this result.
The fact that mRNA-expression models performed well was unsurprising, given
that Colman, et al. had derived the gene set from multiple, independent data sources
and had used two-year survival as their threshold. [1] That their gene set also gener-
alized to TCGA at a significant level lends further credence to the clinical relevance
of that gene set. However, it was somewhat surprising that no model attained
significance for any other data category. Even clinical models, which accounted for age
and KPS—two well-known GBM prognostic variables—failed to reach significance.
Again in this case, it is important to acknowledge that no single performance metric
is adequate. Even though the log-rank statistic was not significant for the NBC
models, the AUC value was relatively high 0.676 (see ROC curve in Figure 4.13). A
look at the Kaplan-Meier survival curves (see Figure 4.14) reveals that a subgroup of
LTS were identified accurately; however, the log-rank statistic was heavily influenced
by the fact that the two curves intersect at one point. Thus in this case, the AUC was
a more telling metric of performance than the log-rank statistic. Because the AUC
is derived from posterior probabilities generated by the classification algorithms, the
ordering of the probabilities influences the AUC value; thus if, for example, the actual
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STS are predicted as STS with greater overall probability than the actual LTS, the
AUC can be informative even when the log-rank statistic and error rate are not.
Across all performance metrics in this experiment, NBC performed better than
C5.0 Decision Trees and SVM. In many cases, C5.0 Decision Trees and SVM predicted
all patients as LTS. NBC may have been less impacted by the class imbalance between
LTS and STS, a factor that can have a strong impact on the performance of many
classifiers, include C5.0 Decision Trees and SVM. [70]
When combining predictions across all data categories and algorithms, no ensemble-
learning approach attained statistical significance (see Table 4.12).
Taken together, these results suggest that multivariate prognosis models trained on
prior-knowledge variables have some ability to identify patients surviving longer than
two years. In particular, performance for somatic-mutation and mRNA expression
models was better than what was obtained using algorithmic variable selection. In
TCGA Experiment 1, the SVM-RFE algorithm ranked IDH1 and TP53 mutations
10th and 37th best across all cross-validation folds. In the same experiment, SVM-
RFE ranked none of the Colman, et al. mRNA expression genes highly; in fact, none
of the nine mRNA expression genes were ranked in the top 1000 across all folds. These
results demonstrate that the algorithmic variable-selection approaches do not always
coincide with prior knowledge, particularly in high-dimensional data sets where a
considerable amount of noise is likely.
4.5 TCGA Experiment 3: Full Data Set,
Empirical Survival Discretization
The experiments so far have used two-year survival, an arbitrarily decided thresh-
old, to distinguish LTS from STS. This section describes the results of an experiment
in which the survival threshold was determined empirically (for each cross-validation
fold).
In preliminary analyses, the empirical split-point method appeared to favor me-
dian survival. A closer look revealed two possible explanations for this apparent bias:
1) because C5.0 Decision Trees—the classification algorithm used by this method—
performs best when the class distribution is balanced, [70] it should naturally bias
toward the median, and 2) the existing method for correcting the error rate against
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chance expectation favors thresholds near the median. The following example illus-
trates the latter point. If the candidate threshold were 100 days, approximately 90%
of patients would be LTS; thus if all patients were predicted by default to be LTS,
the error rate would be 0.100. Then if the algorithm distinguished perfectly between
LTS and STS at this threshold, the error rate would be 0.000, and the improvement
over chance expectations would be 0.100. However, if the candidate threshold were
360 days, approximately 50% of patients would be LTS, and the default error rate
would be 0.500. Then if the algorithm could distinguish only moderately between
LTS and STS—for example, achieving an error rate of 0.390—the improvement over
chance would be 0.110. Thus even though the algorithm classified perfectly at 100
days, the 360-day threshold would be selected. In fact, 100 days would be selected
only if the improvement over chance exceeded 0.100 for no other threshold.
In evaluating ways to address this limitation, two other metrics were considered:
the AUC and log-rank statistic. To compare the effectiveness of these metrics, the
following simulations were performed. Using the actual GBM survival values, a
continuous independent variable was generated for each patient such that patients
below a given, artificially defined threshold had much lower values than patients
above that threshold. Thus it would be expected that the algorithm could differentiate
perfectly between LTS and STS at these thresholds. Figures 4.15, 4.16, and 4.17 show
the results of a simulation where the artificial threshold was 360 days (approximately
median survival in this data set). When the error rate (corrected for what would
be observed if the majority class were predicted by default) or AUC were used, the
simulated threshold was identified correctly and precisely. When the log-rank statistic
was used, several “optimal” thresholds were identified in a tie, and the median of these
values was near the correct threshold. These findings suggest that if the true threshold
for distinguishing LTS from STS is near the median, any of the three metrics could be
used. Figures 4.18, 4.19, and 4.20 show the results of a simulation where the artificial
threshold was 100 days. When the error rate was used, a large number of “optimal”
thresholds (including 100 days) was identified; among these, the median was 235.5
days. A similar result was observed for the log-rank statistic. However, when AUC
was used, the threshold was identified precisely at 99.5 days—no ties occurred. Taken
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together, these results suggest that the AUC is better than the error rate or log-rank
statistic at identifying survival split points. The likely reason for AUC’s advantage is
that its calculation is insensitive to class imbalances. [71]
When the AUC was used as the survival-threshold metric on the TCGA data, the
selected thresholds varied between 69.5 days and 147 days across the cross-validation
folds. Thus, in contrast to the previous experiments, in which most patients were
labeled STS, the great majority of patients were labeled LTS in this experiment.
Because the selected survival thresholds varied across cross-validation folds (see
Figure 4.21), the definition of LTS and STS was different for each fold. For example,
in fold 1, the selected threshold was 90.0 days, while in fold 4, the selected threshold
was 124.5 days. Because of this variability, it would not have been reasonable to
assess overall performance as if the threshold were fixed across all folds (like in
previous experiments). One alternative for addressing this problem is to calculate
the performance metrics separately for each fold, using only the test instances from
that fold. Having obtained a metric for each test set, the overall performance then
would be calculated as the mean performance across the folds. Especially on small
data sets, this approach is conservative for the log-rank statistic because only 1/k
(where k is the number of folds) instances are available for each calculation, so the
upper performance bound is reduced. Additionally, whenever the log-rank statistic
cannot be computed for a given fold (when all predictions are of the same class), its
value must default to zero (equivalent to a p-value of 1.0); consequently, the overall
performance estimate may become even more conservative. Tables 4.13, 4.14, and
4.15 list results for this experiment using the mean-across-folds method of measuring
performance. Several models performed quite well, despite the conservativeness of
this evaluation approach.
In examining the C5.0 models that were used to determine the thresholds, it
became apparent that radiation treatment was an extremely strong predictor of
survival status at the selected thresholds. In cross validation, predictions based on
treatment data (which include radiation) performed exceptionally well by all mea-
sures, across all variable-selection approaches and classification algorithms. Figure
4.22 illustrates that patients who received no radiation treatment survived drastically
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less time than patients who received radiation treatment. Identifying a relationship
between radiation treatment and GBM survival is not novel—multiple studies have
previously observed this relationship, even going back many decades. [6,14,16] In fact,
radiation treatment is part of the standard of care for GBM. [72] However, the fact
that radiation treatment separated STS from LTS so strikingly in this experiment—
despite the presence of thousands of other potential predictor variables—suggests
that patients who receive no radiation treatment can typically expect a very short
survival, regardless of other clinical or biomolecular factors. However, at least for
the TCGA GBM patients, such a strong association between radiation-treatment
status and survival time likely represents a confounding effect. Some patients may
feel they are too old or frail to receive radiation treatment; for these patients, failure
to receive radiation may simply be a surrogate indicator of a patient’s age or overall
health. Indeed, in the TCGA data, patients who chose not to receive radiation
treatment were considerably older (see Figures 4.23) and had lower overall KPS
(see Figure 4.24) than patients who received radiation. Additionally, only a slight
trend exists between patient survival and the number of days before the treatment
started for patients who received radiation treatment (see Figure 4.25); this suggests
that non-radiation-treated patients did not simply delay treatment and then decease
prematurely as a consequence. Taken together, these observations strongly suggest
that including radiation treatment in multivariate models introduces a confounding
effect.
Aside from radiation treatment, drug treatments also appeared to have an effect on
patient survival. However, a closer look at the data revealed a potential confounding
effect. Patients who received radiation treatment also received a greater number
of overall treatments than patients who received no treatment (see Figure 4.26).
Although this finding is expected—radiation-treated patients survive longer and thus
may have opportunities to receive more drug treatments—part of the success in using
treatments to predict survival may stem from this bias.
The SVM algorithm performed relatively well on the mRNA expression data when
RELIEF-F was used for variable selection, attaining a mean AUC of 0.640. Because
radiation treatment was such a strong predictor of survival in this experiment, the
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possibility existed that the expression of some mRNA genes was a surrogate marker for
radiation treatment status. To test this hypothesis, correlation was measured between
the top-ranked mRNA expression genes and radiation treatment using Spearman’s
rank-based rho statistic (excluding missing values). Of the top-500 mRNA genes,
18.0% were correlated with radiation treatment status, while only 8.9% of all mRNA
genes were correlated with radiation treatment status. Accordingly, expression of
these genes may influence tumor aggressiveness to the point that patient well-being
is affected and patients are less likely to receive radiation treatments.
Table 4.16 lists results of the ensemble-learning approaches for this experiment.
All approaches had AUC values that were 0.780 or higher, and most approaches
attained significant log-rank p-values. As expected, the Select Best predictions were
influenced heavily by the individual predictions based on treatment data (including
radiation treatment). However, Stacked Generalization also performed quite well,
even though its second-level predictions accounted not only for treatment-related
predictions but also for predictions based on various categories of molecular data. And
true to its design, the STS-predictive value weighted vote method helped counteract
the effects of class imbalance and performed better than all other voting methods.
Overall, the results from this experiment suggest that a single independent variable
with extremely high prognostic relevance (radiation treatment) can dominate the
threshold-selection method. In this experiment, clinical, treatments, and mRNA
expression data each contained a strong signal that could be discerned by the clas-
sification algorithms. Indeed, the models performed well despite the likely effects of
class imbalance at the selected thresholds. When evaluating the performance of these
models, one should also consider that the conservative mean-across-folds method was
used to calculate the performance metrics.
4.6 TCGA Experiment 4: Radiation-treated
Patients, Median Survival
Because radiation treatment was a strong individual predictor in the previous
experiment and because radiation treatment is part of the standard of care for GBM,
non-radiation-treated patients were excluded for TCGA Experiment 4. Additionally,
to remove any effects of class imbalance, median survival was used as the threshold.
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After excluding patients who received no radiation treatment, 261 patients remained,
and the median survival was 423 days. Table 4.17 lists the results from applying the
RELIEF-F variable-selection approach and the various classification algorithms to this
subset of patients (see Tables 4.18 and 4.19 for results for the other variable-selection
approaches).
Once again, treatment data (not including radiation) distinguished well between
LTS and STS. All three classification algorithms performed well. As in previous
experiments, this success appears to be attributed at least partly to the relationship
between survival and the total number of treatments received. The models that
performed best were based on all five drug-treatment variables; however, interestingly,
the top-ranked treatment variable was other drug treatment—a variable that indicates
whether any of a number of infrequently administered treatments were given. In many
cases, these “other” treatments were targeted therapies (e.g., tamoxifen, rapamycin,
gefitinib, imatinib) that have been used primarily to treat other cancers. In other
cases, the treatments were hormonal (e.g., valproic acid, levetiracetam), chemother-
apy (e.g., carmustine, cisplatin), or immunotherapy treatments (e.g., dendritic cell
vaccine, erlotinib) that each may have a positive effect on some patients but that
individually have not been shown to increase GBM survival in phase III clinical trials.
The clinical data also performed quite well in this experiment. In particular,
C5.0 and NBC models based on the top-ranked clinical variable–age in every cross-
validation fold—attained statistical significance. Figure 4.27 displays Kaplan-Meier
curves for the NBC predictions. This result was unsurprising given that age is a well-
known GBM prognostic variable—the TCGA data show that as age increases, GBM
survival tends to decrease (see Figure 4.28). However, clinical-model performance was
considerably better in this experiment—with median survival as the threshold—than
in the other experiments. It may be that age influences a GBM patient’s prognosis
more strongly when other dominant factors (e.g., no radiation treatment) are not at
play.
Models based on DNA methylation also reached statistical significance. In fact,
nearly every algorithm performed well. Once again, the performance of the models
usually increased as the number of genes in the models increased (see Figure 4.29).
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One factor that may be relevant to global DNA methylation is patient age. Across all
methylation genes profiled, (12.9%) were significantly correlated with age (Wilcoxon
rank-sum test; p < 0.05). Contrarily, only 5.1% of genes were correlated when the
age values were randomly permuted (repeated 100 times). Even though causality
should not be inferred from these calculations, it seems likely that global methylation
patterns are affected by age. A recent study of gastrointestinal cancer demonstrated
just such an effect. [73] As such, survival predictions based on DNA methylation
may be confounded by age effects. To test this supposition further, an additional
experiment was performed using only age and DNA methylation variables (and limited
to patients with data for both categories). Neither data category outperformed the
other in all cases (see Table 4.20). When the two data categories were combined
(into a single data set or via ensemble-learning methods), predictive performance
often improved slightly (see Table 4.21). These results suggest that age and DNA
methylation contain different but complementary prognostic information.
In this experiment, every ensemble method attained statistical significance (see
Table 4.22). All but one (Stacked Generalization) had an AUC value that approached
the maximum individual result for this experiment. In terms of error rate and
AUC, Simple Weighted Vote performed (slightly) better than Majority Vote. Further,
Squared-weighted Vote performed better than Simple Weighted Vote. Additionally,
Weighted Mean Probability performed better than Mean Probability. Similar trends
occurred in the other experiments, a finding that attests to the value of using weight-
based measures to improve ensemble results.
4.7 TCGA Experiment 5: Radiation-treated
Patients, Median Survival,
No Treatment Data
As has been demonstrated previously, a clear relationship exists between the
number of treatments that a patient receives and the number of days a GBM patient
survives (see Figure 4.5). Additionally, at the time of diagnosis, physicians do not
always know which treatments will be administered to a given patient, and physicians
often alter treatment regimens based on a patient’s response to what has already been
administered. Thus the prognostic utility of treatment data is limited, and including
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treatment data in prediction models may cause a confounding effect. Indeed, the
results for TCGA Experiment 4 were consistently good when treatment data were
included in models. In an attempt to avoid such confounding effects, an additional
experiment was conducted in which treatment data were excluded. As in TCGA
Experiment 4, non-radiation-treated patients were excluded from this experiment,
and the median was used as the split point between LTS and STS.
Table 4.23 lists the results from applying the various variable-selection approaches
and classification algorithms to an aggregate data set containing data for all cate-
gories except treatments. And Table 4.24 lists the results from applying the various
ensemble-learning approaches. In some cases, the predictions differentiated between
LTS and STS at statistically significant levels; this finding suggests that models based
solely on clinical, histology, and biomolecular data—which can each be collected
at the time of diagnosis— can be used to inform prognosis predictions. However,
in most cases, the performance of the algorithms was considerably worse than in
TCGA Experiment 4. For example, the best AUC value and log-rank p-value for this
experiment were 0.594 and 7.94e-05, respectively, and in many cases the log-rank
p-values were not statistically significant; however, in TCGA Experiment 4, the
best AUC and log-rank p-value were 0.706 and 9.96e-09, respectively, and all but
two log-rank p-values were statistically significant. Interestingly, the best result for
this experiment was obtained using no variable selection and the SVM classification
algorithm; when these approaches were applied to the data set containing treatment
data (TCGA Experiment 4), the performance was substantially worse (AUC = 0.519,
log-rank p-value = 0.032). Taken together, these differences suggest further that
treatment data can cause a confounding effect and thus should be excluded or at
least treated specially.
In an additional attempt to account for the likely confounding effects of treat-
ments, a follow-on experiment was conducted in which only patients who had been
treated with radiation and temozolomide were included. For the subset of patients
who met these criteria (n = 134), none of the algorithms differentiated between LTS
and STS at a statistically significant level, and the AUC values were near 0.500
(see Tables 4.25 and 4.26). These results suggest the difficulty of using TCGA data
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to differentiate between patients who will respond relatively well to a given drug
treatment and patients who will not respond well. Even though all patients in this
experiment received temozolomide, the treatment regimens were not consistent among
all patients, and many of the patients received various other drug treatments. It is
possible that more effective prediction models could be derived from clinical trials that
administer consistent treatment regimens to all patients. However, clinical trials may
lack sufficient funding to acquire multiple categories of high-throughput molecular
data for an adequately large patient cohort.
4.8 Gene Set Enrichment Analysis of
DNA Methylation Genes
Across all TCGA experiments, the best-performing biomolecular models were
derived using hundreds of DNA methylation variables. A search of the literature
reveals that some of the top-ranked genes have previously been associated with—or
at least have a plausible connection with—tumorigenesis. However, with such a
large number of variables, it can be challenging to assess an entire model’s biological
relevance. GSEA is one approach for providing such interpretation.
The KEGG database contains hundreds of pathway diagrams representing existing
knowledge about protein interactions that affect particular biological processes. Also
included in KEGG are diagrams that represent the proteins involved in particular
cancers. Additionally, KEGG contains aggregate pathway diagrams that combine in-
dividual pathways according to some theme. One such aggregate diagram is pathways
in cancer, which attempts to represent all protein interactions involved in any cancer
type that is currently represented in KEGG.
Initially, the standard GSEA method was applied to the top-1000 ranked (via
RELIEF-F variable selection) methylation genes from TCGA Experiment 4. Table
4.27 lists the most significantly associated pathways. The top pathway, pathways
in cancer, was assigned a p-value of 2.87e-15, indicating a high likelihood that the
selected genes are known to be involved in human cancers in general. Several other
top-ranked pathways represent either individual cancers (e.g., bladder cancer, pan-
creatic cancer) or other pathways that could plausibly drive aberrant tumor growth
(e.g., TGF-beta signaling pathway, focal adhesion). Such findings were expected for
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two reasons: 1) it is reasonable to expect that at least some methylation genes that
differentiate LTS from STS would be associated with known cancer-related pathways,
and 2) the 2189 profiled methylation genes were manually selected by the TCGA
Consortium and thus would likely be biased toward genes from known cancer-related
pathways. As a way to validate the latter assumption, standard GSEA was applied
to the full set of methylation genes that had been profiled (see Table 4.28). Again
in this case, pathways in cancer and several known cancer-related pathways were
identified with extreme significance. These findings confirm that the selected genes
were biased strongly in favor of prior knowledge about cancer. (These findings also
provide evidence that GSEA behaves as expected.)
In an attempt to account for selection bias, the GSEA permutation approach
(described in Methods) was applied to the top-1000 methylation genes. As expected,
pathways in cancer and most other pathways that had been significant prior to the
correction were no longer considered significant (see Table 4.29). However, several
pathways remained significant, including TGF-beta signaling pathway and ErbB sig-
naling pathway, which each are known to play a role in tumorigenesis. [74,75] Also near
the top of the list were NOD-like receptor signaling pathway and Toll-like receptor
signaling pathway, which are involved in generating innate immune responses and
may be interconnected with each other. [76] The immune system is essential not only
for protecting against foreign pathogens but also for attacking tumor cells. [77] Other
significant pathways may not have an intuitive connection with tumorigenesis but do
affect the nervous system (e.g., olfactory transduction, amyotrophic lateral sclerosis,
Huntington’s disease). These pathways may have been selected simply because they
share genes with pathways that drive GBM tumorigenesis. It is also possible that
some pathways (or their subcomponents) that behave aberrantly in other diseases also
are deregulated in some GBM tumors, even though their phenotypic manifestations
are different.
It is important to note that pathways that were statistically significant before bias
correction were not necessarily spurious findings; in fact, these pathways may have
strong relevance to GBM survival. However, the bias-correction technique provides a
way to generate hypotheses about pathways that may influence GBM survival but that
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may have been overlooked in this context. It should also be noted that KEGG is hand
curated and contains only a subset of known biological pathways—any enrichment
study is limited by the knowledge source upon which it is based.
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Table 4.1. Cross-validation results when 900 randomly simulated continuous vari-
ables and 100 randomly simulated binary variables were used. Median survival was
the split point between longer-term survivors and shorter-term survivors. The purpose
of this experiment was to serve as a negative test, ensuring that when no obvious signal
existed in a data set, the performance metrics would indicate such.
Variable Selection Classification Error STS LTS AUC Log-rank
Approach Algorithm Rate Correct Correct p-value
None C5.0 0.188 0.958 0.094 0.526 0.761
None NBC 0.185 0.981 0.000 0.524 0.126
None SVM 0.169 1.000 0.000 0.606 N/A
SVM-RFE C5.0 0.188 0.958 0.094 0.526 0.761
SVM-RFE NBC 0.185 0.981 0.000 0.524 0.126
SVM-RFE SVM 0.169 1.000 0.000 0.579 N/A
RELIEF-F C5.0 0.188 0.958 0.094 0.526 0.761
RELIEF-F NBC 0.169 1.000 0.000 0.581 N/A
RELIEF-F SVM 0.169 1.000 0.000 0.553 N/A
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Table 4.2. Cross-validation results when 900 randomly simulated continuous vari-
ables and 100 randomly simulated binary variables were used. Ensemble-learning
approaches were applied, and median survival was the split point between longer-term
survivors (LTS) and shorter-term survivors (STS). The purpose of this experiment
was to serve as a negative test, ensuring that when no obvious signal existed in a data
set, the performance metrics would indicate such.
Algorithm Error STS LTS AUC Log-rank
Rate Correct Correct p-value
Majority Vote 0.173 0.996 0.000 0.518 2.65e-18*
Simple Weighted Vote 0.173 0.996 0.000 0.518 2.65e-18*
Squared-Weighted Vote 0.173 0.996 0.000 0.518 2.65e-18*
LTS Predictive Value Weighted Vote 0.192 0.958 0.075 0.525 0.939
STS Predictive Value Weighted Vote 0.173 0.996 0.000 0.518 2.65e-18*
Select Best 0.173 0.996 0.000 0.561 0.772
Mean Probability 0.179 0.985 0.019 0.556 0.435
Weighted Mean Probability 0.176 0.985 0.038 0.552 0.925





















Figure 4.1. Receiver operating characteristic curve for validation experiment
in which the C5.0 Decision Trees algorithm attempted to discriminate between
longer-term survivors and shorter-term survivors using 900 randomly simulated con-
tinuous variables and 100 randomly simulated binary variables. No variable selection
was performed.
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Figure 4.2. Kaplan-Meier curves for validation tests in which the C5.0 Decision Trees
algorithm attempted to discriminate between longer-term survivors and shorter-term
survivors using 900 randomly simulated continuous variables and 100 randomly
simulated binary variables. No variable selection was performed.
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Table 4.3. Cross-validation results when 900 randomly generated continuous vari-
ables and 100 randomly generated binary variables were used. Three of the continuous
variables and two of the binary variables were modified to support perfect discrimina-
tion between longer-term survivors (LTS) and shorter-term survivors (STS). Median
survival was the split point between LTS and STS. The purpose of this experiment
was to serve as a positive test, indicating that when an obvious signal existed in a
data set, it could be found.
Variable Selection Classification Error STS LTS AUC Log-rank
Approach Algorithm Rate Correct Correct p-value
None C5.0 0.000 1.000 1.000 1.000 5.43e-40*
None NBC 0.000 1.000 1.000 1.000 5.43e-40*
None SVM 0.000 1.000 1.000 1.000 5.43e-40*
SVM-RFE C5.0 0.000 1.000 1.000 1.000 5.43e-40*
SVM-RFE NBC 0.000 1.000 1.000 1.000 5.43e-40*
SVM-RFE SVM 0.000 1.000 1.000 1.000 5.43e-40*
RELIEF-F C5.0 0.000 1.000 1.000 1.000 5.43e-40*
RELIEF-F NBC 0.000 1.000 1.000 1.000 5.43e-40*
RELIEF-F SVM 0.000 1.000 1.000 1.000 5.43e-40*
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Table 4.4. Cross-validation results when 900 randomly generated continuous vari-
ables and 100 randomly generated binary variables were used. Three of the continuous
variables and two of the binary variables were modified to support perfect discrimina-
tion between longer-term survivors (LTS) and shorter-term survivors (STS). In this
experiment, ensemble-learning approaches were applied, and median survival was the
split point between LTS and STS. The purpose of this experiment was to serve as a
positive test, indicating that when an obvious signal existed in a data set, it could be
found.
Algorithm Error STS LTS AUC Log-rank
Rate Correct Correct p-value
Majority Vote 0.000 1.000 1.000 1.000 5.43e-40*
Simple Weighted Vote 0.000 1.000 1.000 1.000 5.43e-40*
Squared-Weighted Vote 0.000 1.000 1.000 1.000 5.43e-40*
LTS Predictive Value Weighted Vote 0.000 1.000 1.000 1.000 5.43e-40*
STS Predictive Value Weighted Vote 0.000 1.000 1.000 1.000 5.43e-40*
Select Best 0.000 1.000 1.000 1.000 5.43e-40*
Mean Probability 0.000 1.000 1.000 1.000 5.43e-40*
Weighted Mean Probability 0.000 1.000 1.000 1.000 5.43e-40*





















Figure 4.3. Receiver operating characteristic curve for validation tests in which
the C5.0 Decision Trees algorithm attempted to discriminate between longer-term
survivors (LTS) and shorter-term survivors (STS) using 900 randomly simulated
continuous variables and 100 randomly simulated binary variables. Three of the
continuous variables and two of the binary variables were modified to support perfect
discrimination between LTS and STS. No variable selection was performed.
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Figure 4.4. Kaplan-Meier curves for validation tests in which the C5.0 Decision
Trees algorithm attempted to discriminate between longer-term survivors (LTS) and
shorter-term survivors (STS) using 900 randomly simulated continuous variables and
100 randomly simulated binary variables. Three of the continuous variables and two
of the binary variables were modified to support perfect discrimination between LTS
and STS. No variable selection was performed.
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Table 4.5. Cross-validation results when classification algorithms were applied to
several UCI Machine Learning data sets. Values indicate the error rate that was
attained for respective combinations of algorithm and data set. The TunedIT values
represent the mean error rate that was observed on the TunedIT.org web site across
all Weka classifiers that fall under the bayes, functions, and trees categories.
Data Set C5.0 NBC SVM TunedIT
Breast Cancer 0.053 0.026 0.036 0.055
Hepatitis 0.247 0.156 0.221 0.193
Horse Colic 0.119 0.198 0.244 0.192
Ionosphere 0.094 0.077 0.060 0.118
Pima Indians 0.272 0.249 0.352 0.270
Statlog (Australian) 0.157 0.183 0.442 0.168
Statlog (Heart) 0.193 0.159 0.444 0.216
Tic Tac Toe 0.374 0.308 0.069 0.157
Sonar 0.250 0.288 0.327 0.268




































































































































































































































































































































































































































































































































































































































































































































































Table 4.7. Cross-validation results when all patients were included, two-year survival
was the split point between longer-term survivors and shorter-term survivors, and the
SVM-RFE variable-selection approach was used.
Data Algorithm Error STS LTS AUC Log-rank
Category Rate Correct Correct p-value
Clinical
C5.0 0.169 1.000 0.000 0.500 N/A
NBC 0.220 0.938 0.000 0.590 4.46e-05*
SVM 0.204 0.954 0.019 0.455 0.238
Treatments
C5.0 0.169 1.000 0.000 0.500 N/A
NBC 0.182 0.931 0.264 0.707 0.000388*
SVM 0.169 1.000 0.000 0.488 N/A
Histology
C5.0 0.169 1.000 0.000 0.500 N/A
NBC 0.173 0.992 0.019 0.497 0.615
SVM 0.169 1.000 0.000 0.544 N/A
DNA Methylation
C5.0 0.245 0.880 0.100 0.490 0.328
NBC 0.181 0.962 0.067 0.554 0.427
SVM 0.181 0.943 0.167 0.557 0.037*
Somatic Mutations
C5.0 0.196 1.000 0.000 0.500 N/A
NBC 0.277 0.889 0.045 0.559 0.385
SVM 0.214 0.967 0.045 0.395 0.231
DNA Copy Number
C5.0 0.170 0.988 0.020 0.504 0.43
NBC 0.272 0.835 0.180 0.516 0.563
SVM 0.167 0.996 0.000 0.543 0.0797
mRNA Expression
C5.0 0.262 0.861 0.146 0.504 0.892
NBC 0.211 0.918 0.167 0.570 0.108
SVM 0.240 0.887 0.146 0.536 0.551
miRNA Expression
C5.0 0.261 0.846 0.229 0.538 0.987
NBC 0.196 0.952 0.104 0.540 0.657
SVM 0.174 1.000 0.000 0.589 N/A
All Data
C5.0 0.233 0.877 0.226 0.552 0.00338*
NBC 0.204 0.942 0.075 0.561 0.383
SVM 0.169 0.977 0.113 0.643 0.0233*
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Table 4.8. Cross-validation results when all patients were included, two-year survival
was the split point between longer-term survivors and shorter-term survivors, and the
None variable-selection approach was used.
Data Algorithm Error STS LTS AUC Log-rank
Category Rate Correct Correct p-value
Clinical
C5.0 0.169 1.000 0.000 0.500 N/A
NBC 0.166 0.981 0.113 0.683 0.0159*
SVM 0.173 0.996 0.000 0.553 0.614
Treatments
C5.0 0.169 1.000 0.000 0.500 N/A
NBC 0.204 0.915 0.208 0.705 0.00104*
SVM 0.169 1.000 0.000 0.463 N/A
Histology
C5.0 0.169 1.000 0.000 0.500 N/A
NBC 0.173 0.985 0.057 0.474 0.487
SVM 0.169 1.000 0.000 0.524 N/A
DNA Methylation
C5.0 0.324 0.772 0.167 0.469 0.21
NBC 0.170 0.981 0.033 0.584 0.495
SVM 0.160 1.000 0.000 0.547 N/A
Somatic Mutations
C5.0 0.196 0.989 0.045 0.517 0.0854
NBC 0.259 0.922 0.000 0.453 0.0578
SVM 0.205 0.989 0.000 0.397 0.337
DNA Copy Number
C5.0 0.184 0.965 0.060 0.512 0.676
NBC 0.302 0.784 0.260 0.556 0.303
SVM 0.164 1.000 0.000 0.496 N/A
mRNA Expression
C5.0 0.262 0.853 0.188 0.520 0.362
NBC 0.215 0.913 0.167 0.533 0.134
SVM 0.176 0.996 0.000 0.574 0.866
miRNA Expression
C5.0 0.250 0.860 0.229 0.544 0.122
NBC 0.261 0.882 0.062 0.432 0.0669
SVM 0.174 1.000 0.000 0.586 N/A
All Data
C5.0 0.246 0.850 0.283 0.567 0.00474*
NBC 0.240 0.908 0.038 0.503 0.433
SVM 0.169 1.000 0.000 0.632 N/A
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Table 4.9. Cross-validation results when all patients were included, two-year survival
was the split point between longer-term survivors and shorter-term survivors, and the
RELIEF-F variable-selection approach was used.
Data Algorithm Error STS LTS AUC Log-rank
Category Rate Correct Correct p-value
Clinical
C5.0 0.169 1.000 0.000 0.500 N/A
NBC 0.176 0.992 0.000 0.694 0.494
SVM 0.169 1.000 0.000 0.451 N/A
Treatments
C5.0 0.169 1.000 0.000 0.500 N/A
NBC 0.195 0.958 0.057 0.681 0.116
SVM 0.179 0.988 0.000 0.498 0.187
Histology
C5.0 0.169 1.000 0.000 0.500 N/A
NBC 0.173 0.981 0.075 0.463 0.185
SVM 0.169 1.000 0.000 0.505 N/A
DNA Methylation
C5.0 0.239 0.892 0.067 0.480 0.609
NBC 0.186 0.943 0.133 0.600 0.0609
SVM 0.160 1.000 0.000 0.412 N/A
Somatic Mutations
C5.0 0.196 1.000 0.000 0.500 N/A
NBC 0.214 0.967 0.045 0.468 0.366
SVM 0.205 0.989 0.000 0.430 0.337
DNA Copy Number
C5.0 0.164 1.000 0.000 0.500 N/A
NBC 0.308 0.796 0.160 0.512 0.986
SVM 0.164 1.000 0.000 0.488 N/A
mRNA Expression
C5.0 0.262 0.879 0.062 0.471 0.405
NBC 0.262 0.866 0.125 0.489 0.721
SVM 0.186 0.983 0.000 0.465 0.63
miRNA Expression
C5.0 0.217 0.908 0.188 0.548 0.0865
NBC 0.178 0.991 0.021 0.484 0.198
SVM 0.174 1.000 0.000 0.615 N/A
All Data
C5.0 0.204 0.942 0.075 0.509 0.0943
NBC 0.153 0.969 0.245 0.671 1.89e-05*





































Figure 4.5. Patient overall survival versus the total number of treatments received
by each patient.
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Figure 4.6. Kaplan-Meier curves comparing overall survival of patients predicted as
longer-term survivor (LTS) versus patients predicted as shorter-term survivor (STS)
for SVM models trained on DNA methylation data. Support Vector Machines-Recur-
sive Feature Elimination was used for variable selection, and two-year survival was
the split point between LTS and STS.
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Figure 4.7. Area under receiver operating characteristic curve versus number of
DNA methylation genes included in Support Vector Machines models. Support Vector
Machines-Recursive Feature Elimination was used for variable selection, and two-year
survival was the split point between longer-term survivors and shorter-term survivors.
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Figure 4.8. Mean difference in global DNA methylation between longer-term
survivors (LTS) and shorter-term survivors (STS) for each gene that was profiled.
Two-year survival was the split point between LTS and STS.
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Table 4.10. Cross-validation results when all patients were included, two-year sur-
vival was the survival split between longer-term survivors and shorter-term survivors,
and ensemble-learning approaches were applied.
Ensemble Error STS LTS AUC Log-rank
Method Rate Correct Correct p-value
Majority Vote 0.169 1.000 0.000 0.601 N/A
Simple Weighted Vote 0.169 1.000 0.000 0.610 N/A
Squared-Weighted Vote 0.169 1.000 0.000 0.614 N/A
LTS Predictive Value Weighted Vote 0.169 1.000 0.000 0.620 N/A
STS Predictive Value Weighted Vote 0.169 1.000 0.000 0.603 N/A
Select Best 0.192 0.938 0.170 0.676 0.00762*
Mean Probability 0.169 1.000 0.000 0.641 N/A
Weighted Mean Probability 0.169 1.000 0.000 0.651 N/A
Stacked Generalization 0.220 0.900 0.189 0.544 0.0408*
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Figure 4.9. Kaplan-Meier curves comparing overall survival of patients predicted as
longer-term survivor (LTS) versus patients predicted as shorter-term survivor (STS)
for NBC models trained on clinical data. Support Vector Machines-Recursive Feature
Elimination was used for variable selection, and two-year survival was the split point





















Figure 4.10. Receiver operating characteristic curve for NBC models trained on
clinical data. Support Vector Machines-Recursive Feature Elimination was used for
variable selection, and two-year survival was the split point between longer-term
survivors and shorter-term survivors.
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Table 4.11. Cross-validation results when all patients were included and two-year
survival was used as the split point between longer-term survivors and shorter-term
survivors. The prior-knowledge variable-selection approach was used.
Data Algorithm Error STS LTS AUC Log-rank
Category Rate Correct Correct p-value
Clinical
C5.0 0.169 1.000 0.000 0.500 N/A
NBC 0.173 0.981 0.075 0.676 0.0655
SVM 0.169 1.000 0.000 0.508 N/A
Treatments
C5.0 0.169 1.000 0.000 0.500 N/A
NBC 0.169 1.000 0.000 0.596 N/A
SVM 0.169 1.000 0.000 0.497 N/A
Histology
C5.0 0.169 1.000 0.000 0.500 N/A
NBC 0.169 1.000 0.000 0.431 N/A
SVM 0.169 1.000 0.000 0.457 N/A
DNA Methylation
C5.0 0.160 1.000 0.000 0.500 N/A
NBC 0.170 0.987 0.000 0.575 0.302
SVM 0.165 0.994 0.000 0.510 0.916
Somatic Mutations
C5.0 0.196 1.000 0.000 0.500 N/A
NBC 0.196 0.967 0.136 0.520 0.00479*
SVM 0.205 0.989 0.000 0.353 0.628
DNA Copy Number
C5.0 0.164 1.000 0.000 0.500 N/A
NBC 0.266 0.839 0.200 0.504 0.419
SVM 0.164 1.000 0.000 0.428 N/A
mRNA Expression
C5.0 0.172 1.000 0.000 0.500 N/A
NBC 0.211 0.913 0.188 0.538 0.00599*
SVM 0.172 1.000 0.000 0.459 N/A
miRNA Expression
C5.0 0.174 1.000 0.000 0.500 N/A
NBC 0.181 0.978 0.062 0.461 0.171
SVM 0.174 1.000 0.000 0.449 N/A
All Data
C5.0 0.188 0.942 0.170 0.556 0.0299*
NBC 0.243 0.888 0.113 0.567 0.598
SVM 0.169 1.000 0.000 0.416 N/A
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Figure 4.11. Kaplan-Meier curves comparing overall survival of patients predicted
as longer-term survivor versus patients predicted as shorter-term survivor for Na¨ıve
Bayes Classifier models trained on IDH1 and TP53 somatic mutations.
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Figure 4.12. Kaplan-Meier curves comparing overall survival of patients predicted
as longer-term survivor versus patients predicted as longer-term survivor for Na¨ıve





















Figure 4.13. Receiver operating characteristic curve for Na¨ıve Bayes Classifier
models trained on clinical variables that have been reported in the literature to have
prognostic relevance for glioblastoma multiforme.
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Figure 4.14. Kaplan-Meier curves comparing overall survival of patients predicted
as longer-term survivor versus patients predicted as shorter-term survivor for Na¨ıve
Bayes Classifier models trained on clinical variables that have been reported in the
literature to have prognostic relevance for glioblastoma multiforme.
70
Table 4.12. Cross-validation results when all patients were included, two-year
survival was the split point between longer-term survivors and shorter-term survivors,
prior-knowledge variables were used, and ensemble-learning approaches were applied.
Ensemble Error STS LTS AUC Log-rank
Method Rate Correct Correct p-value
Majority Vote 0.169 1.000 0.000 0.587 N/A
Simple Weighted Vote 0.169 1.000 0.000 0.583 N/A
Squared-Weighted Vote 0.169 1.000 0.000 0.583 N/A
LTS Predictive Value Weighted Vote 0.173 0.992 0.019 0.599 0.1
STS Predictive Value Weighted Vote 0.169 1.000 0.000 0.584 N/A
Select Best 0.173 0.981 0.075 0.676 0.0655
Mean Probability 0.169 1.000 0.000 0.637 N/A
Weighted Mean Probability 0.169 1.000 0.000 0.646 N/A
Stacked Generalization 0.176 0.988 0.019 0.504 0.743
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Figure 4.15. Results of empirical split-point selection on data simulated to sup-
port perfect separation between longer-term survivors and shorter-term survivors
at 360-days survival. The error rate (corrected for what would be observed if the
majority class were predicted by default) was used as the evaluation criterion at each
split point. When a tie occurred, the median value was selected.
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Figure 4.16. Results of empirical split-point selection on data simulated to sup-
port perfect separation between longer-term survivors and shorter-term survivors at
360-days survival. The AUC was used as the evaluation criterion at each split point.
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Figure 4.17. Results of empirical split-point selection on data simulated to sup-
port perfect separation between longer-term survivors and shorter-term survivors at
360-days survival. The log-rank statistic was used as the evaluation criterion at each
split point. When a tie occurred, the median value was selected.
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Figure 4.18. Results of empirical split-point selection on data simulated to sup-
port perfect separation between longer-term survivors and shorter-term survivors
at 100-days survival. The error rate (corrected for what would be observed if the
majority class were predicted by default) was used as the evaluation criterion at each
split point. When a tie occurred, the median value was selected.
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Figure 4.19. Results of empirical split-point selection on data simulated to sup-
port perfect separation between longer-term survivors and shorter-term survivors at
100-days survival. The AUC was used as the evaluation criterion at each split point.
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Figure 4.20. Results of empirical split-point selection on data simulated to sup-
port perfect separation between longer-term survivors and shorter-term survivors at
100-days survival. The log-rank statistic was used as the evaluation criterion at each
split point. When a tie occurred, the median value was selected.
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Figure 4.21. Survival split points selected for each cross-validation fold when the
empirical split-point method was applied to the full data set.
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Table 4.13. Cross-validation results when all patients were included and the empiri-
cal split-point method was used to distinguish longer-term survivors from shorter-term
survivors in each cross-validation fold. The SVM-RFE variable-selection approach
was used.
Data Algorithm Error STS LTS AUC Log-rank
Category Rate Correct Correct p-value
Clinical
C5.0 0.137 0.000 1.000 0.500 N/A
NBC 0.154 0.000 0.983 0.611 0.782
SVM 0.150 0.000 0.985 0.491 0.91
Treatments
C5.0 0.118 0.475 0.945 0.710 3.78e-05*
NBC 0.102 0.642 0.953 0.857 1.87e-06*
SVM 0.102 0.400 0.970 0.854 0.000104*
Histology
C5.0 0.137 0.000 1.000 0.500 N/A
NBC 0.153 0.000 0.982 0.539 0.648
SVM 0.137 0.000 1.000 0.558 N/A
DNA Methylation
C5.0 0.169 0.067 0.922 0.494 0.246
NBC 0.133 0.025 0.972 0.497 0.574
SVM 0.161 0.083 0.923 0.530 0.109
Somatic Mutations
C5.0 0.101 0.000 1.000 0.500 N/A
NBC 0.116 0.000 0.983 0.483 0.949
SVM 0.109 0.000 0.992 0.516 0.854
DNA Copy Number
C5.0 0.138 0.000 1.000 0.500 N/A
NBC 0.216 0.062 0.883 0.502 0.481
SVM 0.141 0.013 0.992 0.507 0.0848
mRNA Expression
C5.0 0.233 0.104 0.866 0.485 0.327
NBC 0.183 0.083 0.930 0.521 0.0819
SVM 0.171 0.237 0.897 0.560 0.149
miRNA Expression
C5.0 0.197 0.278 0.877 0.578 0.475
NBC 0.152 0.070 0.965 0.518 0.302
SVM 0.129 0.000 1.000 0.589 N/A
All Data
C5.0 0.144 0.350 0.923 0.637 7.4e-05*
NBC 0.131 0.192 0.958 0.789 0.000548*
SVM 0.099 0.408 0.967 0.845 4.98e-06*
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Table 4.14. Cross-validation results when all patients were included and the empiri-
cal split-point method was used to distinguish longer-term survivors from shorter-term
survivors in each cross-validation fold. The None variable-selection approach was
used.
Data Algorithm Error STS LTS AUC Log-rank
Category Rate Correct Correct p-value
Clinical
C5.0 0.131 0.071 0.988 0.529 0.148
NBC 0.144 0.067 0.974 0.717 0.024*
SVM 0.147 0.000 0.989 0.389 0.842
Treatments
C5.0 0.118 0.475 0.945 0.710 3.78e-05*
NBC 0.102 0.658 0.949 0.864 7.23e-06*
SVM 0.102 0.400 0.970 0.845 0.000104*
Histology
C5.0 0.137 0.000 1.000 0.500 N/A
NBC 0.163 0.000 0.970 0.540 0.437
SVM 0.137 0.000 1.000 0.429 N/A
DNA Methylation
C5.0 0.164 0.158 0.922 0.540 0.114
NBC 0.120 0.000 0.994 0.497 0.929
SVM 0.120 0.000 0.994 0.419 0.712
Somatic Mutations
C5.0 0.101 0.000 1.000 0.500 N/A
NBC 0.116 0.000 0.983 0.506 0.949
SVM 0.101 0.000 1.000 0.680 N/A
DNA Copy Number
C5.0 0.151 0.050 0.981 0.516 0.509
NBC 0.295 0.119 0.786 0.451 0.315
SVM 0.141 0.000 0.996 0.485 0.621
mRNA Expression
C5.0 0.263 0.157 0.817 0.487 0.304
NBC 0.157 0.083 0.957 0.516 0.018*
SVM 0.136 0.000 0.995 0.682 0.966
miRNA Expression
C5.0 0.199 0.259 0.876 0.567 0.498
NBC 0.276 0.071 0.807 0.446 0.306
SVM 0.129 0.000 1.000 0.608 N/A
All Data
C5.0 0.134 0.438 0.931 0.684 0.000118*
NBC 0.160 0.058 0.960 0.501 0.056
SVM 0.141 0.000 0.996 0.701 0.862
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Table 4.15. Cross-validation results when all patients were included and the empiri-
cal split-point method was used to distinguish longer-term survivors from shorter-term
survivors in each cross-validation fold. The RELIEF-F variable-selection approach
was used.
Data Algorithm Error STS LTS AUC Log-rank
Category Rate Correct Correct p-value
Clinical
C5.0 0.137 0.000 1.000 0.500 N/A
NBC 0.205 0.154 0.885 0.707 0.146
SVM 0.186 0.142 0.913 0.613 0.129
Treatments
C5.0 0.118 0.475 0.945 0.710 3.78e-05*
NBC 0.102 0.642 0.953 0.856 1.87e-06*
SVM 0.106 0.367 0.974 0.864 0.000201*
Histology
C5.0 0.137 0.000 1.000 0.500 N/A
NBC 0.163 0.000 0.970 0.536 0.54
SVM 0.141 0.000 0.996 0.434 0.88
DNA Methylation
C5.0 0.191 0.000 0.909 0.454 0.511
NBC 0.146 0.033 0.960 0.501 0.439
SVM 0.146 0.000 0.964 0.452 0.512
Somatic Mutations
C5.0 0.101 0.000 1.000 0.500 N/A
NBC 0.126 0.000 0.971 0.439 0.699
SVM 0.109 0.000 0.992 0.399 0.854
DNA Copy Number
C5.0 0.138 0.000 1.000 0.500 N/A
NBC 0.401 0.447 0.620 0.589 0.246
SVM 0.138 0.000 1.000 0.500 N/A
mRNA Expression
C5.0 0.157 0.068 0.956 0.512 0.393
NBC 0.203 0.073 0.901 0.452 0.187
SVM 0.146 0.037 0.975 0.640 0.433
miRNA Expression
C5.0 0.182 0.084 0.920 0.502 0.335
NBC 0.256 0.151 0.791 0.476 0.386
SVM 0.129 0.000 1.000 0.599 N/A
All Data
C5.0 0.134 0.333 0.950 0.642 0.000458*
NBC 0.131 0.333 0.945 0.814 0.000262*


































Figure 4.22. Overall survival for patients receiving radiation treatment versus
































































































































Figure 4.26. Overall number of treatments versus radiation treatment status.
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Table 4.16. Cross-valiation results when all patients were included, the empirical
survival split-point method was used to distinguish longer-term survivors from short-
er-term survivors in each cross-validation fold, and ensemble-learning approaches were
applied.
Ensemble Error % STS % LTS AUC Log-rank
Method Rate Correct Correct p-value
Majority Vote 0.137 0.000 1.000 0.847 N/A
Simple Weighted Vote 0.134 0.013 1.000 0.855 0.241
Squared-Weighted Vote 0.128 0.042 1.000 0.858 0.0377*
LTS Predictive Value Weighted Vote 0.137 0.000 1.000 0.851 N/A
STS Predictive Value Weighted Vote 0.115 0.246 0.975 0.856 0.000125*
Select Best 0.099 0.675 0.949 0.860 9.77e-07*
Mean Probability 0.137 0.000 1.000 0.849 N/A
Weighted Mean Probability 0.134 0.013 1.000 0.860 0.241
Stacked Generalization 0.121 0.567 0.931 0.749 2.33e-06*
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Table 4.17. Cross-validation results when non-radiation-treated patients were ex-
cluded and median survival (423 days) was used as the split point between longer-term
survivors and shorter-term survivors. The RELIEF-F variable-selection approach was
used.
Data Algorithm Error STS LTS AUC Log-rank
Category Rate Correct Correct p-value
Clinical
C5.0 0.398 0.542 0.662 0.602 0.000483*
NBC 0.418 0.466 0.700 0.590 0.000581*
SVM 0.467 0.473 0.592 0.541 0.157
Treatments
C5.0 0.333 0.771 0.562 0.666 4.27e-07*
NBC 0.333 0.702 0.631 0.656 3.5e-06*
SVM 0.318 0.756 0.608 0.640 3.97e-07*
Histology
C5.0 0.521 0.573 0.385 0.479 0.145
NBC 0.475 0.374 0.677 0.511 0.411
SVM 0.533 0.351 0.585 0.421 0.0891
DNA Methylation
C5.0 0.429 0.629 0.500 0.565 0.103
NBC 0.325 0.888 0.419 0.657 1.32e-05*
SVM 0.429 0.809 0.284 0.566 0.0785
Somatic Mutations
C5.0 0.459 0.880 0.188 0.534 0.278
NBC 0.480 0.880 0.146 0.479 0.157
SVM 0.449 0.560 0.542 0.534 0.126
DNA Copy Number
C5.0 0.492 1.000 0.000 0.500 N/A
NBC 0.449 0.868 0.224 0.562 0.33
SVM 0.516 0.209 0.768 0.480 0.759
mRNA Expression
C5.0 0.487 0.479 0.548 0.513 0.808
NBC 0.457 0.546 0.539 0.553 0.0383*
SVM 0.491 0.529 0.487 0.535 0.277
miRNA Expression
C5.0 0.536 0.475 0.452 0.463 0.819
NBC 0.498 0.051 0.965 0.519 0.674
SVM 0.494 0.373 0.643 0.519 0.637
All Data
C5.0 0.310 0.756 0.623 0.689 9.96e-09*
NBC 0.333 0.817 0.515 0.687 4.66e-07*
SVM 0.318 0.725 0.638 0.702 2.56e-07*
88
Table 4.18. Cross-validation results when non-radiation-treated patients were ex-
cluded and median survival (423 days) was used as the split point between longer-term
survivors and shorter-term survivors. The None variable-selection approach was used.
Data Algorithm Error STS LTS AUC Log-rank
Category Rate Correct Correct p-value
Clinical
C5.0 0.452 0.489 0.608 0.548 0.0039*
NBC 0.410 0.580 0.600 0.626 4.25e-05*
SVM 0.571 0.305 0.554 0.432 0.0145*
Treatments
C5.0 0.318 0.756 0.608 0.682 3.97e-07*
NBC 0.333 0.702 0.631 0.656 3.5e-06*
SVM 0.318 0.756 0.608 0.642 3.97e-07*
Histology
C5.0 0.533 0.641 0.292 0.467 0.0192*
NBC 0.487 0.382 0.646 0.510 0.455
SVM 0.525 0.359 0.592 0.445 0.86
DNA Methylation
C5.0 0.436 0.573 0.554 0.564 0.135
NBC 0.380 0.843 0.351 0.628 0.00119*
SVM 0.399 0.921 0.216 0.586 0.0022*
Somatic Mutations
C5.0 0.541 0.740 0.167 0.453 0.0708
NBC 0.490 0.680 0.333 0.409 0.893
SVM 0.459 0.300 0.792 0.543 0.404
DNA Copy Number
C5.0 0.504 0.915 0.064 0.489 0.689
NBC 0.508 0.651 0.328 0.472 0.443
SVM 0.508 0.116 0.880 0.500 0.705
mRNA Expression
C5.0 0.462 0.605 0.470 0.537 0.843
NBC 0.449 0.639 0.461 0.537 0.084
SVM 0.530 0.630 0.304 0.457 0.6
miRNA Expression
C5.0 0.511 0.466 0.513 0.490 0.395
NBC 0.515 0.568 0.400 0.480 0.722
SVM 0.528 0.492 0.452 0.475 0.0395*
All Data
C5.0 0.368 0.588 0.677 0.632 1.46e-05*
NBC 0.475 0.641 0.408 0.547 0.0646
SVM 0.475 0.412 0.638 0.519 0.032*
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Table 4.19. Cross-validation results when non-radiation-treated patients were ex-
cluded and median survival (423 days) was used as the split point between longer-term
survivors and shorter-term survivors. The SVM-RFE variable-selection approach was
used.
Data Algorithm Error STS LTS AUC Log-rank
Category Rate Correct Correct p-value
Clinical
C5.0 0.456 0.565 0.523 0.544 0.00267*
NBC 0.395 0.702 0.508 0.614 9.54e-06*
SVM 0.433 0.519 0.615 0.559 0.00218*
Treatments
C5.0 0.318 0.756 0.608 0.682 3.97e-07*
NBC 0.333 0.702 0.631 0.656 3.5e-06*
SVM 0.318 0.756 0.608 0.641 3.97e-07*
Histology
C5.0 0.502 0.763 0.231 0.497 0.832
NBC 0.494 0.344 0.669 0.492 0.726
SVM 0.525 0.412 0.538 0.463 0.347
DNA Methylation
C5.0 0.485 0.629 0.378 0.504 0.96
NBC 0.387 0.798 0.392 0.598 0.00311*
SVM 0.417 0.764 0.365 0.590 0.0701
Somatic Mutations
C5.0 0.551 0.680 0.208 0.444 0.227
NBC 0.490 0.800 0.208 0.424 0.53
SVM 0.480 0.220 0.833 0.462 0.682
DNA Copy Number
C5.0 0.500 0.977 0.008 0.492 0.319
NBC 0.484 0.550 0.480 0.493 0.358
SVM 0.476 0.233 0.824 0.483 0.79
mRNA Expression
C5.0 0.513 0.555 0.417 0.486 0.932
NBC 0.483 0.504 0.530 0.518 0.579
SVM 0.517 0.454 0.513 0.502 0.551
miRNA Expression
C5.0 0.511 0.568 0.409 0.488 0.709
NBC 0.481 0.898 0.130 0.510 0.363
SVM 0.558 0.398 0.487 0.403 0.248
All Data
C5.0 0.349 0.618 0.685 0.651 0.000187*
NBC 0.398 0.641 0.562 0.618 0.0142*
SVM 0.352 0.702 0.592 0.656 7.31e-06*
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Figure 4.27. Kaplan-Meier curves comparing overall survival of patients predicted
as longer-term survivor (LTS) versus shorter-term survivor (STS) when the NBC
algorithm was applied to clinical data. Support Vector Machines-Recursive Feature
Elimination was used for variable selection, non-radiation-treated patients were ex-



































Figure 4.28. Patient overall survival versus age at pathologic diagnosis.
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Figure 4.29. Area under receiver operating characteristic curve versus number of
DNA methylation genes included in Na¨ıve Bayes Classifier models. Median survival
was the split point between longer-term survivors and shorter-term survivors, and
variables were ranked using Support Vector Machines-Recursive Feature Elimination.
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Table 4.20. Cross-validation results when age at diagnosis and DNA methylation
data were used as data categories. No variable selection was applied, non-radia-
tion-treated patients were excluded, and median survival was the split point between
longer-term survivors and shorter-term survivors. Only patients with data for both
data categories were included.
Data Algorithm Error STS LTS AUC Log-rank
Category Rate Correct Correct p-value
Age
C5.0 0.442 0.416 0.730 0.573 0.0145*
NBC 0.411 0.843 0.284 0.634 0.0436*
SVM 0.460 0.910 0.095 0.492 0.609
DNA Methylation
C5.0 0.485 0.618 0.392 0.505 0.754
NBC 0.399 0.843 0.311 0.576 0.000354*
SVM 0.448 0.876 0.162 0.523 0.0208*
All Data
C5.0 0.485 0.618 0.392 0.505 0.754
NBC 0.399 0.843 0.311 0.577 0.000354*
SVM 0.405 0.820 0.324 0.624 0.00657*
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Table 4.21. Cross-validation results when ensemble-learning approaches were ap-
plied to age data and DNA methylation data. Non-radiation-treated patients were
excluded, and median survival was the split point between longer-term survivors
and shorter-term survivors. Only patients with data for both data categories were
included.
Ensemble Error STS LTS AUC Log-rank
Method Rate Correct Correct p-value
Majority Vote 0.436 0.876 0.189 0.593 0.11
Simple Weighted Vote 0.436 0.843 0.230 0.576 0.03*
Squared-Weighted Vote 0.436 0.843 0.230 0.575 0.03*
LTS Predictive Value Weighted Vote 0.429 0.843 0.243 0.585 0.0144*
STS Predictive Value Weighted Vote 0.423 0.843 0.257 0.566 0.0244*
Select Best 0.460 0.798 0.230 0.530 0.304
Mean Probability 0.436 0.685 0.419 0.611 0.0174*
Weighted Mean Probability 0.436 0.685 0.419 0.592 0.0174*
Stacked Generalization 0.479 0.764 0.230 0.497 0.755
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Table 4.22. Cross-validation results non-radiation-treated patients were excluded,
median survival (423 days) was the split point between longer-term survivors and
shorter-term survivors, and ensemble-learning approaches were applied.
Ensemble Error STS LTS AUC Log-rank
Method Rate Correct Correct p-value
Majority Vote 0.364 0.725 0.546 0.696 1.69e-05*
Simple Weighted Vote 0.349 0.733 0.569 0.703 1.03e-06*
Squared-Weighted Vote 0.326 0.740 0.608 0.706 7.29e-08*
LTS Predictive Value Weighted Vote 0.337 0.725 0.600 0.704 2.63e-07*
STS Predictive Value Weighted Vote 0.352 0.718 0.577 0.703 1.29e-06*
Select Best 0.318 0.733 0.631 0.682 3.65e-07*
Mean Probability 0.352 0.863 0.431 0.689 9.29e-07*
Weighted Mean Probability 0.356 0.840 0.446 0.697 3.9e-06*
Stacked Generalization 0.460 0.588 0.492 0.540 0.0978
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Table 4.23. Cross-validation results when non-radiation-treated patients were ex-
cluded and median survival (423 days) was used as the split point between longer-term
survivors and shorter-term survivors. In this experiment, all data categories except
Treatments were combined into a single data set.
Variable Selection Classification Error STS LTS AUC Log-rank
Approach Algorithm Rate Correct Correct p-value
None C5.0 0.475 0.550 0.500 0.525 0.665
None NBC 0.479 0.641 0.400 0.546 0.0638
None SVM 0.418 0.481 0.685 0.594 7.94e-05*
SVM-RFE C5.0 0.475 0.573 0.477 0.525 0.0988
SVM-RFE NBC 0.429 0.679 0.462 0.580 0.0119*
SVM-RFE SVM 0.448 0.542 0.562 0.565 0.0106*
RELIEF-F C5.0 0.498 0.679 0.323 0.501 0.379
RELIEF-F NBC 0.441 0.702 0.415 0.586 0.0957
RELIEF-F SVM 0.452 0.527 0.569 0.556 0.139
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Table 4.24. Cross-validation results when non-radiation-treated patients were ex-
cluded, median survival (423 days) was used as the split point between longer-term
survivors and shorter-term survivors, and ensemble-learning approaches were applied.
All data categories except Treatments were used.
Ensemble Error STS LTS AUC Log-rank
Method Rate Correct Correct p-value
Majority Vote 0.437 0.687 0.438 0.584 0.00222*
Simple Weighted Vote 0.433 0.679 0.454 0.586 0.00238*
Squared-Weighted Vote 0.437 0.679 0.446 0.590 0.00111*
LTS Predictive Value Weighted Vote 0.444 0.649 0.462 0.586 0.0113*
STS Predictive Value Weighted Vote 0.444 0.672 0.438 0.587 0.00372*
Select Best 0.437 0.649 0.477 0.578 0.00411*
Mean Probability 0.444 0.855 0.254 0.583 0.0224*
Weighted Mean Probability 0.433 0.840 0.292 0.584 0.00572*
Stacked Generalization 0.494 0.473 0.538 0.506 0.298
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Table 4.25. Cross-validation results when only patients who received radiation and
temozolomide treatment were included. Median survival (423 days) was used as
the split point between longer-term survivors and shorter-term survivors. All data
categories except Treatments were combined into a single data set.
Variable Selection Classification Error STS LTS AUC Log-rank
Approach Algorithm Rate Correct Correct p-value
None C5.0 0.530 0.448 0.493 0.470 0.352
None NBC 0.515 0.284 0.687 0.503 0.987
None SVM 0.530 0.403 0.537 0.419 0.159
SVM-RFE C5.0 0.470 0.537 0.522 0.530 0.297
SVM-RFE NBC 0.507 0.522 0.463 0.515 0.704
SVM-RFE SVM 0.575 0.418 0.433 0.430 0.18
RELIEF-F C5.0 0.507 0.627 0.358 0.493 0.991
RELIEF-F NBC 0.552 0.463 0.433 0.460 0.267
RELIEF-F SVM 0.507 0.448 0.537 0.457 0.235
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Table 4.26. Cross-validation results when only patients who received radiation
and temozolomide treatment were included and ensemble-learning approaches were
applied. Median survival (423 days) was the split point between longer-term survivors
and shorter-term survivors. All data categories except Treatments were used.
Ensemble Error STS LTS AUC Log-rank
Method Rate Correct Correct p-value
Majority Vote 0.515 0.284 0.687 0.485 0.454
Simple Weighted Vote 0.530 0.299 0.642 0.479 0.241
Squared-Weighted Vote 0.537 0.299 0.627 0.477 0.246
LTS Predictive Value Weighted Vote 0.537 0.284 0.642 0.478 0.19
STS Predictive Value Weighted Vote 0.537 0.299 0.627 0.485 0.199
Select Best 0.493 0.552 0.463 0.537 0.727
Mean Probability 0.515 0.239 0.731 0.495 0.637
Weighted Mean Probability 0.515 0.269 0.701 0.490 0.366
Stacked Generalization 0.515 0.448 0.522 0.485 0.141
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Table 4.27. Results of standard (noncorrected) GSEA analysis applied to top-1000
ranked DNA methylation genes by the RELIEF-F algorithm. Patients receiving no
radiation treatment were excluded, and median survival was used as the split point.
The KEGG pathways most highly enriched for the genes are displayed.
KEGG Pathway p-value
Pathways in cancer 2.87e-15





Chronic myeloid leukemia 4.1e-06
Prostate cancer 4.46e-06
MAPK signaling pathway 5.35e-06
Amyotrophic lateral sclerosis (ALS) 6.11e-06
Toll-like receptor signaling pathway 9.85e-06
Melanoma 1.24e-05




Fc epsilon RI signaling pathway 5.09e-05
Cytokine-cytokine receptor interaction 7e-05
Leukocyte transendothelial migration 8.94e-05
Axon guidance 0.000109
101
Table 4.28. Results of standard (noncorrected) GSEA analysis applied to all
methylation genes (when patients receiving no radiation treatment were excluded
and median survival was used as the split point).
KEGG Pathway p-value






p53 signaling pathway 4.53e-09
Cytokine-cytokine receptor interaction 5.25e-09





Chronic myeloid leukemia 3.73e-07
MAPK signaling pathway 4.18e-07
Basal cell carcinoma 6.88e-07
Leukocyte transendothelial migration 1.92e-06
Pancreatic cancer 2e-06
Colorectal cancer 2.11e-06
Hematopoietic cell lineage 2.68e-06
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Table 4.29. Results of permutation-corrected GSEA analysis applied to top-1000
ranked DNA methylation genes by the RELIEF-F algorithm (when patients receiving
no radiation treatment were excluded and median survival was used as the split point).
KEGG Pathway p-value
Olfactory transduction 0.001
Amyotrophic lateral sclerosis (ALS) 0.004
TGF-beta signaling pathway 0.005
Toll-like receptor signaling pathway 0.008
NOD-like receptor signaling pathway 0.011
Tyrosine metabolism 0.018
Huntington’s disease 0.019
ErbB signaling pathway 0.024
Pancreatic cancer 0.027
Fc epsilon RI signaling pathway 0.035
Progesterone-mediated oocyte maturation 0.036
Glycine, serine and threonine metabolism 0.038
Chronic myeloid leukemia 0.039
PPAR signaling pathway 0.04




Because GBM is a complex disease for which patient survival time is influenced by
a variety of heterogeneous factors, one objective of this study was to assess how well
multivariate prediction algorithms could differentiate between GBM patients who
would survive a relatively long or short time after diagnosis. Using ML-Flex, the
custom software package developed for this study, various algorithms were applied
to retrospective GBM data from TCGA. In many cases, the algorithms identified
subsets of patients that experienced significantly longer or shorter survival than the
remaining patients.
A desirable outcome of this study might have been that one particular algorithm
or data category performed well in all cases and thus could have been favored for
further development of GBM prognosis models. However, in this study, classification
performance varied substantially across algorithms and data categories, even though
some data categories appeared to be more informative than others. Across the various
experiments, better performance was typically observed when variable selection was
performed than when all variables were included in the models; this finding coincides
with the expectation that many variables have little or no ability to differentiate
between LTS and STS. Among classification algorithms, NBC performed quite well
and often (at least slightly) better than the other algorithms. However, in many cases,
C5.0 Decision Trees and SVM performed (at least slightly) better than NBC. Such
variability is not a surprise considering the diversity of the algorithmic approaches—a
given algorithm may be suited well to a particular type of data and not to others.
Across the experiments, the data categories that appeared to contain most prognostic
relevance were clinical, treatments, and DNA methylation; in some experiments,
models based on the remaining data categories—histology, somatic mutations, DNA
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copy number, mRNA expression, and miRNA expression—performed moderately
well, but the algorithms had only marginal success with these categories overall.
(Potential reasons for the relatively poor performance of these categories are described
in the Limitations section below.)
Rather than compare performance extensively across algorithms or data cate-
gories, this study employed ensemble-learning approaches in an attempt to aggregate
evidence across multiple algorithms and data categories. In a few cases, the ensemble
methods outperformed all individual algorithms. But in general, the ensemble meth-
ods’ main advantage was their consistency. While performance varied considerably
across algorithms and data categories, the ensemble methods often approximated the
best individual performers. In some cases, the ensemble methods performed well
because they identified and favored one individual algorithm/category combination
that generalized well; in other cases, the ensemble methods appear to have extracted
complementary evidence from several algorithms/categories. These findings suggest
that in the absence of a priori knowledge about which algorithm or data category
would be most useful for making survival predictions, ensemble methods may be the
most effective choice.
Limited predictive performance was observed for multivariate models based on
previously reported GBM prognostic variables when the survival threshold was two
years (the threshold used most frequently in the literature). Subsequent experiments
revealed that better performance could be attained when the survival threshold was
different from two years (and when the variables are not limited by prior knowledge).
At least two factors likely influenced these performance differences: 1) prior knowledge
about factors influencing GBM prognosis is incomplete, 2) the choice of survival
threshold influences predictive performance strongly due to class imbalances.
In evaluating the biological relevance of methylation genes that helped differentiate
between LTS and STS, GSEA analyses revealed a strong bias in favor of genes
from pathways already believed to affect tumorigenesis. The permutation method
attempted to correct for this bias and generated hypotheses about pathways that may
drive GBM tumor aggressiveness but may have been overlooked in this context. For
the best-performing DNA methylation models, some hypotheses pointed to the body’s
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innate immune response as a prognostically relevant biological mechanism for GBM.
Researchers are actively studying the immune system’s role in suppressing tumor
growth, and immunotherapies are being investigated as a means to help the immune
system target tumors. In fact, at least one such therapy has already shown promise
for GBM. In a series of clinical trials conducted at Duke University, patients with an
in-frame deletion in the EGFR gene (EGFRvIII) were vaccinated with peptide-pulsed
dendritic cells; after treatment, the patients experienced antitumor immune responses
with no serious adverse events, and some have had remarkable recoveries. [78]
In this study, three metrics—error rate, AUC, and log-rank statistic—were used to
assess model performance. The error rate is frequently reported in machine-learning
studies due to its simplicity of calculation and interpretation. However, care must
be taken to interpret the error rate when the class distribution is imbalanced—an
important consideration in this study. Although the AUC’s method of calculation
is relatively complex—and thus less intuitive—the AUC’s interpretation remains
consistent for any class distribution. Additionally, the AUC accounts not only for
discrete classes predicted by an algorithm but also for the confidence with which those
predictions are made. (In this study, the AUC estimates the likelihood that a classifier
assigned a randomly chosen STS a higher probability of being STS than a randomly
chosen LTS.) This property also suits the AUC well for assessing model performance in
inner cross-validation folds and for serving as a weight in ensemble-learning methods.
On the other hand, a disadvantage of the AUC is that it depends on the quality
of the algorithms’ posterior probabilities; some algorithms, such as C5.0 Decision
Trees, are designed only to give discrete probabilities. An important advantage of
the log-rank statistic is its familiarity to clinicians. The log-rank p-value provides
an intuitive—though arbitrarily determined—assessment of a given model’s quality
via “statistical significance” thresholds. However, a potential disadvantage of the
log-rank statistic is that it weighs outliers heavily. In sum, none of these metrics is
adequate in isolation, and sometimes they conflict with each other. Perhaps the best
way to assess model performance is to focus on models that perform well according to
all three metrics yet to keep an eye open for special cases that otherwise demonstrate
clinical relevance (such as the IDH1/TP53 somatic-mutation models).
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Finally, it should be noted that even though multivariate models in this study
predicted survival status poorly for many data categories, it should not be inferred
that effective models are impossible—or even unlikely—to be developed for those data
categories. Such inferences could become Type II errors (false negatives) as methods
of developing such models are refined. An important goal of this study was to apply
commonly used, general-purpose algorithms to the TCGA data for GBM and gain a
sense for the performance levels that can be attained when such algorithms are tested
in a rigorous and consistent fashion. Other algorithms that are more sophisticated
or better suited to the poor-performing data categories may prove valuable in future
studies.
5.2 Major Contributions
In 2007, Dupuy and Simon surveyed the literature for studies that had examined a
relationship between high-throughput molecular data and cancer outcomes. [79] For
21 of 42 studies that were examined in detail, the authors expressed concern over
methodological flaws in the studies’ experimental designs. For example, some cross-
validated studies performed variable selection on the entire data set rather than within
each training set, an approach that can bias results tremendously. Methodological
concerns and differences between studies may arise partly because independent labs
each develop custom software to perform their analyses, yet considerable time and
software-engineering effort is required to ensure validity. ML-Flex was developed as
a means to address these gaps by performing cross-validation studies in a rigorous,
consistent, and repeatable fashion. Additionally, because repositories like TCGA
contain gigabytes of data, the time required to construct multivariate models is
an important consideration. Despite the growing availability of high-performance
computational resources, most software is not designed to take advantage of multiple
central processing units (CPUs) within each server or multiple processing cores within
each CPU. Thus in the development of ML-Flex, an additional effort was made to
ensure experiments could be executed in a time-efficient manner. ML-Flex uses the
threading capability within the Java virtual machine to capitalize on such resources.
No software package with this architecture is freely available to researchers at this
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time. Thus plans are in place to share ML-Flex with the broader research community
in hopes that it will become a standard tool for performing large-scale, cross-validated
studies. The extensible nature of ML-Flex should enable developers to customize its
use to a broad range of research purposes.
Previous studies of GBM prognosis typically have focused on one or two categories
of patient data. Contrarily, in this study, eight categories of patient data have been
tested side by side in a comparative assessment of prognostic relevance. Although care
must be taken to consider the limitations of such an analysis (especially the possibility
of false-negative results), comparative assessments across data categories may help
guide investment of financial resources for future analyses. In particular, researchers
and funding agencies must weigh the incremental costs of acquiring multiple categories
of high-throughput molecular data for each patient.
Although other research groups are analyzing the GBM data in TCGA, no other
study has reported the use of supervised-learning algorithms to analyze this data set
in relation to prognosis. Thus this study has the potential to pave the way for future
supervised-learning studies in TCGA (and elsewhere).
Because various types of molecular aberrations can influence tumor growth, a key
goal of the TCGA Consortium is to facilitate development of methods that integrate
data across modalities. This study has demonstrated two approaches for performing
integrative analyses: 1) combining all data into an aggregate data set and allowing
multivariate algorithms to model intercategory relationships at a granular level, and 2)
making multivariate predictions for each data category separately and then combining
predictions at a coarse level using ensemble-learning approaches. Although neither
approach resulted in predictive performance that was consistently better than the
best single-category models, the integrative methods used in this study demonstrate
alternatives for researchers to consider as multimodal data sets become more common.
It may be that such methods perform considerably better when applied to other
diseases or when the number of component algorithms is increased.
In this study, algorithmic refinements have also been explored. Firstly, the Edger-
ton, et al. method of selecting survival split points was modified to use the AUC rather
than the chance-corrected error rate. As described in the Results section, a simulation
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study demonstrates that this modification should result in better precision when the
split point is away from the median. Secondly, three novel, weight-based ensemble
methods were developed and applied. While the performance of these methods did not
always exceed previously developed methods, they consistently performed better than
majority vote and simple weighted vote and thus show promise for further refinement.
5.3 Limitations
Because biomedical informatics is a relatively young field—especially in the realm
of genetics/genomics research—detailed protocols do not exist for performing exper-
iments such as those in this study. General guidelines must be followed to ensure
statistical and methodological rigor; however, many seemingly minor decisions—each
of which could have a drastic impact on the results—must be made. In this study,
an attempt has been made to default such decisions toward the simplest approach.
However, arbitrary decisions sometimes had to be made. This section describes such
issues as well as extraneous factors that may have impacted performance. It is
hoped that this study will serve as a starting point for future research by elucidating
methodological factors that must be considered in performing such a study.
The TCGA data are being provided by several research centers throughout the
United States. While special efforts are being made to ensure consistency in specimen
handling, tumor-sample quality, and clinical data definitions, the TCGA data by
nature are heterogeneous and likely to contain noise that could impact predictive
performance. Acknowledging this limitation, an added measure of confidence can be
placed in models that do perform well on this data set. Additionally, because the data
come from different institutions and are handled by a variety of people, data quality
can be affected. Thus manual examination of the data and some subjective inter-
pretation were necessary for this study. For example, the drug-treatment data often
contained multiple spellings (including mispellings) for a given drug, and sometimes a
drug’s commercial name was listed instead of its generic name. These inconsistencies
were manually corrected before executing the experiments in this study.
Ideally, TCGA would contain data only for GBM patients who had been treated
uniformly (as in clinical trials). Such a design would enable assessments of the
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effectiveness of specific treatments and of cofactors that may influence treatment
responses. However, until recently, no drug treatment had been shown to improve
GBM survival in a phase III clinical trial [2]; thus the standard of care has not
included specific drug treatments until recently. Consequently, a wide variety of drug
treatments (and treatment regimens) have been administered to TCGA patients.
The various treatments likely affected patient survival to differing degrees—as al-
ready noted, the total number of drug treatments received is associated with patient
survival—so treatment status may have a confounding effect on other factors that
affect survival. Thus even though this study attempted to address a clinician’s
need to prospectively estimate patient prognosis at the time of diagnosis—treatment
regimens are not always known at the time of diagnosis—treatment data were included
in this study to estimate the effects that treatments have on survival. Various
alternatives could be employed to deal with the treatment-data confounding effects;
for example, 1) analyses may be limited to patients who received specific treatments,
2) treatment data may be excluded from analyses, and 3) predictions based on
treatment data may be used as covariates in multivariate survival analyses. The
first two of these approaches were employed in TCGA Experiment 5, and the results
were mixed. Filtering patients by treatments may result in subpopulations that are
inadequately sized to derive generalizable models or attain statistical significance—
especially considering the fact that sample sizes in TCGA are limited to begin with.
Including treatment-based predictions as covariates in multivariate analyses would
provide an estimate of the prognostic value offered by a given data category and
algorithm, independent of treatment status; however, this estimate would provide
little additional insight due to the heterogeneous nature of the treatment data.
Two variables that are not recorded in TCGA but that may have offered valuable
insights are tissue anatomic site and year of diagnosis. In the Lamborn, et al. study,
[11] tissue anatomic site showed promise as a prognostic factor; it is plausible that
GBM tumors differ in their aggressiveness, operability, and in the effects they have
on cognitive function, depending on the location of the brain from which the tumor
arises. An evaluation of the relationship between year of diagnosis and patient survival
may have offered insights into confounding effects that may result from changes in
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treatments, surgical techniques, methods of tumor-sample preservation, etc. that have
occurred across the span of years during which the TCGA patients were diagnosed
and treated.
One decision that may have impacted the results considerably is the choice of
data normalization and summarization techniques. For example, when multiple
histology values were provided (e.g., for the top and bottom of slides or for mul-
tiple samples), the mean value was used; however, it may be that the maximum or
minimum value would better represent these features. Additionally, treatment data
were transformed into binary values, even though patients who received multiple
doses of a given drug may have gained more benefit than patients who received
a single dose. Additionally, all biomolecular data were summarized according to
higher-level functional categories. For example, somatic-mutation, DNA methylation,
and mRNA expression data were summarized at the gene level; DNA copy-number
data were summarized by chromosomal band; and miRNA data were summarized
by known gene targets. Although summarizing raw data may sometimes reduce
signal, summarization methods enable easier interpretation, reduce computational
demands, and may represent underlying biological mechanisms better than raw data.
An interesting area for future research would be to assess the effects of various
data-summarization approaches on downstream classification performance.
Transforming time-to-event data into a binary outcome (e.g., STS, LTS) can
result in a loss of information [79]; however, to be consistent with prior studies that
have attempted to separate patients into discrete groups, [1, 19, 20] survival was also
discretized in this study. Discretizing survival can also introduce bias if the two
groups have different censorship structures [79]; however, such bias was avoided in
this study by excluding patients who were still alive (n = 74) when the analysis
was performed. Although this exclusion affected sample size only moderately in this
study, such an approach may not be acceptable when studying other cancer types for
which survival is generally longer. Consequently, multivariate prediction algorithms
that retain survival as a continuous variable and account for censorship status (thus
allowing living patients to be included) may be more suitable for general application.
Alternatively, living patients who have survived longer than the discretization thresh-
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old can be included in analyses and labeled LTS; however, to maintain consistency
across experiments, that approach was not used in this study.
Instead of discretizing survival using either an abritrary threshold or the empirical
split-point method, an alternative approach would be to examine the survival distri-
bution visually and seek to identify natural groupings that have occurred. Figure 5.1
shows the overall distribution of survival times for GBM patients used in this study.
No clear bimodal distribution exists in the data; however, noticeable irregularities in
the distribution exist around 100 days, 500 days, and 800 days. The irregularity at
100-days survival likely represents (at least in part) the differences in survival between
patients who received radiation treatment or not. The irregularities near 500 days and
800 days have no straightforward explanation and may represent thresholds dividing
groups of patients whose tumors have different biological underpinnings. One way to
formalize this approach would be to use a technique like k-means clustering to identify
groups within the distribution quantitatively. One challenge with using this approach
is that sample sizes in TCGA are limited. Thus using a population-level database of
GBM patient survival—such as what may be found in public cancer registries—could
be useful for deriving general-purpose thresholds.
Across the experiments performed in this study, the same data set was evaluated
multiple times via cross validation. Although cross validation maintained statistical
rigor for each experiment, the possibility exists that enough attempts to attain
statistical significance would eventually result in log-rank p-values that fall below the
alpha threshold (i.e., p < 0.05) by random chance. Researchers have developed many
approaches to account for this so-called “multiple-testing bias”; however, no approach
is standardly applied in this setting. Perhaps the most conservative correction for
multiple tests is the Bonferroni approach, which divides the alpha threshold by
the total number of tests; p-values lower than the corrected threshold then are
considered significant. Accounting for all combinations of variable-selection approach,
classification algorithm, and data category that were tested, plus the various ensemble
approaches that were tested, the total number of tests across all experiments was
342. Thus according to the Bonferroni correction, log-rank p-values would need to
be lower than 0.0001462 to be considered significant. Several results from this study
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attained this level of significance; however, the Bonferroni correction, which assumes
independence between tests, is overly conservative in this setting because many of
the tests were highly interrelated. A reasonable, though less rigorous, approach to
accounting for multiple tests across experiments is simply to place most emphasis
on the data categories that perform consistently well. For example, models based on
clinical, treatment, and DNA methylation data performed well for multiple algorithms
and in multiple experiments, despite differences in survival threshold. Models based
on mRNA expression also performed well, though their performance was less robust
across algorithms and experiments.
One other way to address multiple-testing concerns is to evaluate prognostic
models on an (or preferably multiple) external data set. If a model performs well on
independent sets of patients, confidence in the model increases substantially. However,
TCGA is unique in its breadth of data, making it infeasible at this time for individual
labs to perform external validation. Consequently, this study has simulated external
validation with a cross-validation approach. However, as the TCGA Consortium
continues to collect data for additional GBM patients, the results of this study can
be validated on a separate set of GBM patients.
5.4 Opportunities for Future Work
The multivariate algorithms employed in this study can be configured using var-
ious parameters. For simplicity, default parameters were selected in most cases.
However, performance can vary dramatically as such parameters are modified. Thus it
is possible that parameters other than those used in this study could result in improve
performance. One way to estimate optimal parameters for a given classification task
is to experiment with various settings in internal cross-validation folds and select
settings that perform best internally. A slightly different but related technique, which
could be employed using ML-Flex’s current design, is to treat different parameter
configurations as separate algorithms and use ensemble-learning approaches to com-
bine evidence across the various configurations. If a single configuration performed
exceptionally better than other configurations in internal folds, Select Best should
account for it; otherwise, the collective wisdom produced by the various configurations
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may prove beneficial.
TCGA contains various categories of biomolecular data. For some data cate-
gories (e.g., DNA copy number, DNA methylation, mRNA expression), data have
been profiled using multiple high-throughput technology platforms. For simplicity of
computation and interpretation, only a single platform was examined in this study
for each data category. However, ML-Flex’s extensible design makes it possible to
process data from any platform that produces text-based output. Two interesting
avenues for future research would be 1) to compare predictive performance across
platforms and 2) to combine evidence across platforms via ensemble approaches. For
the latter, an additional refinement could be to develop a hierarchical model in which
ensemble methods derive an aggregate prediction for each data category, and then
aggregate predictions are combined into an overall prediction.
As already noted, class imbalance can affect classification performance because
many algorithms are designed for scenarios where the classes are balanced. A recent
study observed that class imbalance especially affects high-dimensional data sets,
unless a very strong signal exists in the data. [80] In this study, class imbalance
often appeared to affect ensemble-learning approaches even more markedly than
individual algorithms. For this study, two novel ensemble-learning methods—STS
predictive-value weighted vote and LTS predictive-value weighted vote—were devel-
oped in an attempt to counter class-imbalance effects. Although these methods
did not always outperform other ensemble approaches, they showed promise as a
means to place emphasis on the minority class. In future research, these methods
will be explored further and compared with existing methods for dealing with class
imbalance, including cost matrices.
When survival values are discretized, the performance of classification algorithms
may suffer, particularly for patients whose survival times are near the discretization
threshold. In lieu of discretizing survival, an alternative approach would be to retain
survival as a continuous variable and use regression algorithms to obtain continuous
predictions for each patient. The log-rank statistic and Kaplan-Meier curves—familiar
and well-accepted standards for assessing clinical relevance—require that patients be
assigned to discrete groups. One way to meet this requirement would be to apply a
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clustering algorithm to the continuous survival predictions and compare the actual
survival values of patients in each cluster. Such an approach may outperform methods
that either 1) discretize survival or 2) perform unsupervised clustering on the entire
data set. Additionally, this approach could also be used as an ensemble-learning
method because it could account for predictions from multiple data categories and
algorithms.
Although this study has focused on GBM, the first cancer type with a substantial
amount of data in TCGA, the U.S. government recently announced that an additional
$275 million would be invested in TCGA and that it will eventually cover more than
20 cancer types [81]; those efforts are now ongoing. As new data sets become available
in TCGA, the tools and methods of this study can be applied to other cancer types.
Although prognosis has been the outcome of interest in this study, the ML-Flex
package can be used to perform multivariate analyses for any outcome relevant to a
given cancer type. Because ML-Flex will be made available publicly, other researchers
will be able to explore relationships in TCGA that otherwise would have required a
considerable software-engineering effort.
5.5 Relevance to Biomedical Informatics
Shortliffe and Blois have defined biomedical informatics as ”the scientific field that
deals with biomedical information, data, and knowledge—their storage, retrieval, and
optimal use for problem solving and decision making.” [82] Although other definitions
exist, this definition has been used commonly in the field.
Accordingly, the purpose of this study was to help solve an important biomedical
problem: short patient survival after GBM diagnosis. In pursuit of this goal, large
quantities of biomedical data were retrieved, stored, and processed. Scientific tools
and techniques were developed and applied in an attempt to convert data to infor-
mation, which could then be interpreted and potentially be considered knowledge. It
is hoped that such knowledge will serve as building blocks for future research and
ultimately have a positive impact on human health.
Biomedical informatics is a highly interdisciplinary field. In isolation, the fields
of biology, medicine, computer science, information systems, or statistics lack the
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perspective and tools necessary for studies such as this one to be accomplished.
However, as these fields continue to become connected through biomedical informatics


















The aggressive nature of GBM leaves clinicians with a relatively short time span
to determine optimal treatments for each patient. Although radiation treatment,
surgical resection, and temozolomide treatment have shown promise for lengthening
GBM survival times, few patients survive longer than five years after diagnosis. A
better understanding of factors that are associated with GBM survival—and thus
that may indicate a lack of response to standard treatments—could help clinicians
prioritize patients for clinical trials and help patients make decisions about entering
such trials. An increased understanding of the biological mechanisms that drive tumor
aggressiveness—and that may differentiate the most (or least) lethal tumors from the
remaining tumors—may also lead researchers to molecularly targeted treatments that
improve patient outcomes. [83]
Some prognostic insight may be gained from considering a patient’s age or KPS
or from examining a patient’s tumor under a microscope. However, these data
have limited ability to distinguish between LTS and STS. Even though biomolecular
aberrations are at the root of tumor initiation and progression, [84] no prognosis
model based on biomolecular data is in widespread use by clinicians who treat GBM
patients. [1] Until recent years, bench researchers studying GBM prognosis have been
limited to small-scale efforts that evaluated one or a few biomolecular variables at a
time. Fortunately, technological advances are making it possible for researchers to
examine the biomolecular characteristics of cancer cells with increasing granularity
and at decreasing costs. (The magnitude of such data sets will only increase as “next-
generation” sequencing technologies become more commonplace.) The resulting data
deluge necessitates the use of sophisticated informatics techniques to store, retrieve,
and analyze the data sets; however, implementation of such techniques often lies
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outside the expertise of bench researchers and clinicians.
Although some prognostic factors may determine a GBM patient’s fate in isolation,
it is likely that multiple factors work in concert to influence tumor aggressiveness
and ultimately survival for many patients. In some cases, tens, hundreds, or even
thousands of factors may each have a subtle impact on tumor activity. Complicating
the situation further, prognostic factors may interact with each other synergistically
or antagonistically. For reasons such as these, multivariate approaches to devel-
oping prognosis models are warranted—traditionally used statistical techniques for
predicting survival may not be suitable in the face of thousands of independent
variables, strong dependencies between variables, and multiple scales of measurement.
Moreover, it is essential that analyses be conducted in a systematic and consistent
way to ensure validity, repeatability, and comparability across studies.
In this study, a variety of multivariate approaches were applied to various cate-
gories of data for a cohort of GBM patients, and predictive performance was evaluated
in a robust, cross-validated design. Although performance of the algorithms varied
substantially across the data categories, some models performed well for all three
metrics—particularly models based on age, treatments, and DNA methylation.
Even though a long road may still lie ahead for researchers working to eradicate
devastating diseases like GBM, informatics tools and techniques such as those pre-
sented in this study promise to guide researchers in their efforts to improve outcomes
and explain the biological underpinnings of disease.
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